rna
interfer
rnai
extens
employ
vivo
research
sinc
use
first
demonstr
mammalian
cell
year
ago
design
rule
improv
routin
possibl
obtain
reagent
suppress
express
gene
desir
time
increas
understand
molecular
basi
unwant
side
effect
led
develop
chemic
modif
strategi
mitig
concern
deliveri
remain
singl
greatest
hurdl
widespread
adopt
vivo
rnai
method
howev
excit
advanc
made
new
deliveri
system
develop
may
help
overcom
barrier
review
discuss
advanc
rnai
biochemistri
biolog
impact
vivo
use
provid
overview
select
public
demonstr
interest
applic
principl
emphasi
place
work
synthet
small
interf
rna
sirna
publish
sinc
first
instal
review
appear
research
search
new
improv
method
effici
alter
gene
express
decad
landmark
discoveri
identifi
doublestrand
rna
dsrna
sequencespecif
mrnainterf
speci
trigger
studi
varieti
system
uncov
evolutionari
conserv
form
rna
interfer
rnai
across
almost
phyla
mechanist
rnai
wellunderstood
numer
review
articl
avail
provid
reader
thorough
understand
basic
biochemistri
involv
briefli
nt
small
interf
rna
sirna
duplex
function
molecul
provid
sequencespecif
target
select
subsequ
mrna
cleavag
part
multicompon
rnainduc
silenc
complex
risc
characterist
overhang
strand
recogn
paz
domain
argonaut
key
protein
compon
risc
paz
domainbind
aid
orient
sirna
risc
defin
polar
load
risc
scan
avail
mrna
sequenc
mediat
cleavag
mrna
suffici
homolog
exist
sirna
guid
strand
initi
cleavag
event
convert
mrna
substrat
degrad
cellular
importantli
administr
sirna
cell
cultur
achiev
ic
valu
low
picomolar
rang
demonstr
rnai
potent
mechan
gene
inhibit
factor
favor
therapeut
signific
driver
motiv
develop
method
use
rnai
vivo
five
year
ago
review
appear
molecular
therapi
address
rapid
ascent
rnai
discoveri
routin
tool
use
research
therapeut
aspir
one
conclud
statement
review
follow
rnaibas
drug
alreadi
clinic
trial
hope
sirna
therapeut
receiv
us
food
drug
administr
approv
distant
futur
time
around
publish
report
vivo
use
sirna
could
found
today
vivo
studi
sirna
becom
almost
commonplac
result
variou
ongo
clinic
trial
await
anticip
accord
recent
review
nearli
clinic
trial
open
studi
uniqu
sirnasmal
hairpin
rna
shrna
base
drug
includ
particip
biotechnologypharmaceut
compani
academicbas
research
center
today
search
pubm
specifi
keyword
sirna
vivo
rnai
vivo
return
almost
refer
present
review
contain
littl
discuss
basic
rnai
biochemistri
focus
recent
advanc
relev
use
sirna
vivo
research
tool
therapeut
like
previou
review
present
work
gener
restrict
use
chemic
synthes
sirna
focu
chemistri
methodolog
optim
commerci
avail
rnai
therapeut
justifi
howev
discuss
advanc
field
also
serv
highlight
characterist
sirnabas
therapeut
current
hurdl
technolog
becom
us
food
drug
administrationapprov
platform
treatment
human
diseas
review
first
discuss
recent
improv
sirna
site
select
design
chemic
modif
method
reduc
offtarget
effect
ote
ie
practic
aspect
sirna
technolog
import
understand
start
vivo
studi
provid
illustr
exampl
use
differ
approach
perform
experi
vivo
use
synthet
sirna
far
mani
studi
publish
recent
year
mention
everi
contribut
field
author
apolog
advanc
whose
work
includ
herein
manuscript
discuss
sirna
vivo
studi
summar
tabl
detail
featur
studi
shown
supplementari
tabl
larg
number
report
employ
synthet
sirna
anim
studi
discuss
review
still
rel
young
field
rapidli
develop
explor
wide
varieti
new
methodolog
report
prove
reproduc
reader
caution
evalu
individu
techniqu
care
expect
method
discuss
herein
work
appli
system
interest
earli
work
sirna
efficaci
demonstr
sirna
equipot
initi
attempt
predict
site
target
within
long
mrna
target
focus
defin
similar
experiment
valid
sirna
principl
learn
studi
establish
gener
set
characterist
enrich
potent
sirna
base
sequenc
thermodynam
work
well
contribut
effort
recent
review
firstgener
design
tool
develop
rel
small
number
valid
sirna
focus
specif
featur
sirna
consider
given
structur
target
mrna
howev
basic
principl
establish
overal
guaninecytosinecont
asymmetr
thermost
etc
remain
import
criteria
effect
sirna
design
today
advanc
predict
model
secondgener
algorithm
develop
recent
year
abil
model
predict
potent
sequenc
improv
use
thousand
sequenc
train
set
employ
sophist
machin
learn
tool
autom
neural
network
ann
support
vector
machin
svm
use
permit
broader
rang
attribut
given
sequenc
consid
select
analysi
routin
well
establish
structur
mrna
target
signific
effect
follow
exampl
literatur
highlight
signific
role
mrna
secondari
structur
play
direct
correl
demonstr
rnai
knockdown
effici
local
free
energi
target
region
mrna
similar
studi
regard
access
mrna
guid
strandrisc
process
calcul
probabl
mrna
target
unpair
measur
energi
requir
disrupt
mrna
secondari
structur
consid
multipl
secondari
structur
mrna
sirna
partit
function
calcul
shown
local
structur
target
region
import
predictor
sirna
function
studi
establish
method
incorpor
calcul
mrna
sirna
structur
featur
site
select
algorithm
improv
predict
abil
calcul
consid
sirna
sequenc
recent
public
provid
detail
discuss
topic
note
review
other
cite
provid
tabl
referenc
publicli
avail
train
set
sirna
knockdown
data
well
onlin
tool
use
sirna
design
wellestablish
chemic
synthes
sirna
host
issu
affect
function
especi
use
vivo
set
full
repertoir
immunecompet
cell
present
nucleas
stabil
strand
load
ote
immunogen
biodistribut
potenc
halflif
factor
consid
improv
make
sirna
suitabl
vivo
use
especi
therapeut
sever
recent
review
provid
thorough
discuss
chemic
modif
strategi
avail
use
sirna
illustr
chemic
structur
use
section
highlight
recent
advanc
examin
use
chemic
modif
new
variat
structur
design
sirna
improv
function
overcom
nucleas
degrad
signific
challeng
administ
nucleic
acid
kind
vivo
sirna
mechan
cleavag
proce
transesterif
chemic
modif
replac
hydroxyl
provid
protect
degrad
positionspecif
manner
likewis
backbon
modif
also
make
rna
less
labil
substrat
nucleas
mani
backbon
modif
modif
increas
nucleas
stabil
also
confer
increas
bind
affin
duplex
stabil
modif
extens
studi
dna
rna
lock
nucleic
acid
lna
fana
modif
use
rna
replac
vari
level
success
extent
chemic
modif
need
vari
use
exampl
method
employ
vivo
administr
nake
sirna
may
requir
greater
stabil
sirna
inject
complex
polymer
deliveri
vehicl
provid
physic
protect
rna
cargo
particularli
extracellular
rna
commonli
use
modif
natur
occur
nucleotid
toxic
report
use
fact
use
modif
gener
reduc
toxic
synthet
dsrna
introduc
mammalian
cell
hoerter
walter
demonstr
exonucleas
play
signific
role
guid
strand
degrad
thermodynam
asymmetri
sirna
drive
guid
strand
incorpor
risc
lower
thermodynam
stabil
guid
strand
render
region
suscept
activ
decreas
doublestrand
natur
duplex
guid
antisens
strand
complet
degrad
hour
human
serum
wherea
passeng
sens
strand
thermodynam
stabil
show
retent
fulllength
strand
durat
assay
modif
residu
guid
strand
full
passeng
strand
modif
prevent
sirna
degrad
hour
significantli
limit
effect
nucleas
attack
hour
serum
yet
retain
potenc
choung
colleagu
also
show
use
modif
simpl
altern
pattern
strand
extend
stabil
human
serum
hour
similarli
kraynack
baker
demonstr
fulli
passeng
strand
toler
led
risc
activ
retain
potenc
addit
exonucleas
activ
rnase
alik
endonucleas
activ
serum
may
significantli
contribut
sirna
degrad
turnov
inhibitor
rnase
improv
sirna
function
halflif
least
singlestrand
form
modif
confer
signific
stabil
endonucleas
attack
provid
less
protect
exonucleas
degrad
suggest
modif
impart
greater
nucleas
resist
may
particularli
signific
role
near
sequenc
termini
surprisingli
sequenc
sirna
directli
affect
nucleas
stabil
absenc
chemic
modif
unmodifi
sequenc
may
suffici
inher
stabil
use
vivo
modif
also
extens
use
sirna
rna
aptam
field
long
histori
use
modif
experi
suggest
substitut
fluorin
gener
welltoler
vivo
howev
toxicolog
modif
extens
studi
rna
interestingli
one
studi
demonstr
fulli
sirna
nearli
potent
unmodifi
sirna
reduc
green
fluoresc
protein
gfp
express
yet
capabl
surviv
incub
rnase
complet
degrad
unmodifi
sirna
nevertheless
usual
use
combin
modif
modif
similar
howev
fana
orient
equatori
unlik
modif
discuss
point
small
number
sirna
studi
date
modif
demonstr
improv
luciferas
knockdown
fourfold
measur
reduc
luciferas
activ
mrna
level
addit
stabil
sirna
fetal
calf
serum
extend
minut
unmodifi
sirna
hour
lna
bicycl
nucleic
acid
ribos
connect
via
methylen
bridg
modif
lock
sugar
backbon
conform
rna
form
lead
increas
duplex
stabil
higher
melt
temperatur
improv
nucleas
resist
lna
modif
must
use
sparingli
sirna
extens
substitut
gener
result
loss
potenc
sirna
minim
modifi
lna
residu
maintain
potenc
show
increas
serum
stabil
beyond
hour
wherea
sequenc
unmodifi
form
complet
degrad
hour
mous
serum
similar
result
report
mice
dose
intraven
iv
chitosanformul
sirna
sparingli
modifi
lna
base
formul
show
effect
gfp
knockdown
bronchoepithelium
antisens
oligonucleotid
aso
heavili
modifi
lna
base
phosphorothio
ps
internucleosid
linkag
caus
signific
hepatotox
mice
similar
report
appear
lnamodifi
sirna
possibl
inher
lower
toxic
type
compound
dsrna
phosphodiest
linkag
use
reduc
number
modifi
residu
although
dna
normal
thought
chemic
modif
substitut
dna
place
rna
residu
sirna
nevertheless
repres
modif
introduc
chang
steric
electron
characterist
natur
sirna
design
chang
colleagu
use
dna
mixmer
hybrid
passeng
strand
duplex
unmodifi
guid
strand
suppress
express
uitei
colleagu
incorpor
dna
base
seed
region
base
guid
strand
maintain
sirna
potenc
simultan
decreas
ote
improv
sequenc
specif
may
result
reduc
stabil
dnarna
hybrid
duplex
compar
rnarna
hybrid
work
wengel
kjem
colleagu
produc
varieti
novel
chemic
modif
use
sirna
alkyl
variou
substitu
shown
aminoethyl
guanidinoethyl
cyanoethyland
allylmodif
effect
increas
serum
stabil
perhap
greater
util
properti
unlock
nucleic
acid
una
acycl
lack
bond
ribos
ring
modifi
sirna
describ
sever
recent
public
una
success
combin
lna
improv
rel
stabil
sirna
termini
furthermor
sirna
una
modif
base
show
increas
stabil
mous
serum
well
improv
egfp
knockdown
dose
subcutan
sc
xenograft
tumor
model
human
pancreat
cancer
mice
una
also
use
highthroughput
studi
identifi
key
locat
destabil
sirna
could
lead
reduct
ote
discuss
greater
detail
alter
sugarphosph
backbon
significantli
increas
nucleas
stabil
commonli
use
chemistri
class
ps
modif
nonbridg
oxygen
replac
sulfur
group
internucleosid
phosphat
linkag
modif
extens
histor
usag
vivo
drug
human
clinic
trial
pharmacolog
toxicolog
well
establish
least
context
singlestrand
aso
limit
use
ps
modif
improv
nucleas
stabil
retain
function
potenc
furthermor
psmodifi
sirna
may
show
improv
cellular
uptak
absenc
transfect
reagent
howev
nake
deliveri
alway
less
potent
assist
deliveri
landmark
report
first
demonstr
system
dose
sirna
nonhuman
primat
util
sirna
contain
ps
linkag
well
residu
silenc
apob
anoth
report
sirna
contain
similar
backbon
conjug
vitamin
e
guid
strand
endogen
dice
antiapob
sirna
confirm
northern
blot
analysi
produc
function
sirna
apolipoprotein
b
apob
level
mice
reduc
liver
follow
iv
administr
control
nontocopherolmodifi
antiapob
sirna
show
evid
silenc
role
chemic
modif
sirna
use
vivo
discuss
specif
exampl
endogen
sirna
dsrna
central
duplex
domain
strand
first
gener
chemic
synthes
artifici
sirna
mimick
natur
product
replac
overhang
dna
typic
use
tt
dimer
soon
becam
clear
use
dna
base
overhang
slightli
reduc
potenc
compar
natur
rna
design
offer
real
advantag
furthermor
recent
report
demonstr
dt
overhang
sirna
inhibit
thymidyl
synthas
import
enzym
cell
growth
metabol
lead
unwant
ote
therefor
prefer
employ
target
sequencematch
rna
rna
deriv
overhang
least
guid
strand
asymmetr
design
singl
posit
guid
strand
appear
bia
load
strand
desir
offer
increas
potenc
asymmetr
duplex
design
employ
suppress
apob
express
nonhuman
primat
varieti
sirna
design
variant
describ
may
improv
properti
natur
structur
despit
good
evid
design
increas
potenc
decreas
side
effect
synthet
sirna
remain
primari
compound
use
today
recent
review
chang
colleagu
discuss
variou
design
strategi
tri
date
improv
properti
synthet
trigger
rnai
present
review
briefli
consid
subset
design
variant
reader
refer
chang
detail
blunt
rna
duplex
length
rang
extens
use
especi
heavili
modifi
rna
pattern
reduc
load
passeng
strand
risc
compound
design
taken
clinic
trial
silenc
therapeut
absenc
limit
paz
domain
bind
may
advers
affect
potenc
howev
singlestrand
tradit
sirna
highli
suscept
nucleas
attack
retain
presenc
vivo
assur
longer
blunt
design
also
highli
also
use
good
result
although
duplex
length
would
normal
process
dicer
size
chemic
modif
pattern
employ
studi
prevent
dice
occur
seem
interfer
risc
load
function
potenc
natur
pathway
risc
format
start
process
long
dsrna
dicertrbp
heterodim
complex
nascent
sirna
remain
associ
dicertrbp
transfer
convert
singlestrand
form
guid
strand
retain
risc
activ
capabl
sequencespecif
cleavag
target
mrna
propos
invok
natur
risc
load
pathway
use
synthet
dicersubstr
trigger
rnai
might
show
improv
potenc
differ
properti
seen
use
synthet
dicer
product
small
synthet
dsrna
size
rang
test
abil
function
sirna
found
site
longer
duplex
inde
potent
cognat
sirna
howev
site
two
design
equipot
sirna
potent
origin
compound
test
blunt
unmodifi
rna
duplex
process
dicer
multipl
sirna
domin
speci
vari
sequenc
context
unpredict
way
use
asymmetr
rna
duplex
passeng
strand
guid
strand
singl
guid
strand
show
much
predict
dice
pattern
substitut
two
dna
base
passeng
strand
blunt
end
improv
reliabl
dicer
cleavag
new
design
propos
gener
use
dicersubstr
sirna
dsirna
observ
duplex
orient
dice
compound
influenc
strand
load
risc
dicer
shown
directli
particip
strand
select
posit
sirna
within
dicer
complex
pivot
determin
strand
remain
risc
like
sirna
dsirna
modifi
substitut
show
improv
properti
increas
nucleas
stabil
reduc
immun
activ
long
appropri
domain
remain
unmodifi
site
dicer
cleavag
occur
increas
length
synthet
shrna
may
also
improv
potenc
howev
long
structur
rna
difficult
manufactur
convers
shown
synthet
hairpin
shorter
length
may
also
improv
function
compound
present
barrier
synthesi
sirna
variant
shorter
tradit
size
also
success
asymmetr
sirna
guid
strand
pair
passeng
strand
short
retain
high
function
elimin
potenti
ote
passeng
strand
short
function
risc
group
found
shorter
sirna
show
reduc
potenc
compar
sirna
tradit
length
complex
design
use
effect
petrova
colleagu
report
use
forksirna
duplex
improv
nucleas
resist
prolong
silenc
twice
long
unmodifi
analog
forksirna
work
base
earlier
public
report
strand
thermodynam
destabil
caus
incorpor
strateg
posit
mismatch
led
improv
antisens
strand
incorpor
risc
increas
sirna
potenc
ote
ote
includ
activ
innat
immun
system
sirna
well
unintend
knockdown
nontarget
mrna
either
mrna
cleavag
mirna
pathway
histor
experi
use
aso
initi
led
research
expect
simpl
homolog
search
could
use
predict
risk
target
unintend
gene
share
sequenc
similar
sirna
homolog
search
remain
necessari
step
elimin
overt
crossreact
screen
stringenc
inadequ
predict
actual
risk
ote
birmingham
colleagu
demonstr
high
complementar
throughout
entir
guid
strand
requir
signific
ote
mediat
littl
domain
compris
guid
seed
region
nucleotid
guid
strand
seven
base
sequenc
motif
abund
transcriptom
number
mrna
contain
potenti
seedregion
bind
site
given
sirna
usual
number
thousand
importantli
presenc
seed
match
mrna
necessarili
correl
capabl
regul
mirnalik
interact
sirna
fact
sequenc
match
kind
show
effect
predict
site
real
versu
site
short
region
homolog
consequ
difficult
make
screen
predict
ote
difficult
heptam
motif
uniformli
express
mammalian
gene
correl
exist
frequenc
express
motif
rel
risk
sequenc
bear
trigger
ote
recent
chemic
modif
variat
sirna
design
success
employ
limit
risk
ote
jackson
colleagu
found
place
singl
residu
posit
guid
strand
suffici
block
ote
due
seed
region
complementar
mani
sequenc
test
unfortun
modif
pattern
reduc
potenc
sirna
sequenc
context
depend
may
univers
solut
problem
ote
result
seed
homolog
also
reduc
substitut
dna
base
seed
region
complementari
region
passeng
strand
along
guid
strand
passeng
strand
use
luciferas
express
plasmid
report
four
differ
unmodifi
sirna
known
signific
ote
aris
passeng
strand
unwant
activ
block
modif
dna
base
passeng
strand
dna
base
guid
strand
select
placement
lna
residu
may
help
reduc
ote
effici
modif
transfect
sirna
contain
variou
lna
pattern
compar
effect
differ
gene
global
gene
profil
certain
lna
modif
pattern
capabl
reduc
ote
without
reduc
potenc
lna
modif
stabil
ie
increas
sirna
duplex
recent
bramsen
colleagu
demonstr
place
singl
una
residu
seed
region
posit
guid
strand
particularli
effect
decreas
ote
incorpor
una
modif
posit
effect
variant
found
reduc
ote
compar
chemic
modif
test
variou
posit
within
set
sirna
specif
three
differ
target
benefici
effect
una
base
posit
guid
strand
independ
verifi
vaish
colleagu
addit
found
ad
una
residu
strand
increas
stabil
sirna
presum
reduc
attack
place
una
residu
passeng
strand
block
abil
particip
risc
therebi
elimin
ote
origin
strand
gener
rule
modif
elimin
passeng
strand
function
risc
prevent
ote
may
aris
strand
may
also
improv
potenc
guid
strand
reduc
competit
risc
load
varieti
approach
use
block
passeng
strand
particip
risc
recogn
present
natur
sirna
chemic
synthes
sirna
exhibit
potenc
whether
group
present
rapidli
convert
form
cell
transfect
group
block
abil
passeng
strand
phosphoryl
reduc
abil
strand
load
risc
reduc
ote
would
otherwis
aris
strand
block
strand
alway
complet
effect
howev
addit
strategi
may
also
need
employ
small
intern
segment
interf
sisi
rna
design
variant
passeng
strand
synthes
two
separ
oligo
anneal
adjac
intact
guid
strand
mimick
natur
cleavag
use
enhanc
lna
modif
improv
stabil
hybrid
short
passeng
strand
fragment
improv
perform
approach
segment
passeng
strand
inact
risc
therefor
contribut
ote
mammal
evolv
two
activ
immun
pathway
counter
wide
rang
biolog
threat
encount
environ
adapt
immun
system
employ
receptor
system
hundr
thousand
gene
element
recombin
mutat
evolv
antibodi
tcell
respons
exquisit
specif
adapt
immun
take
month
mount
maxim
respons
contrast
innat
immun
system
reli
small
number
fix
receptor
identifi
respond
presenc
known
potenti
foreign
molecul
high
risk
host
innat
immun
rapid
respond
limit
collect
predefin
trigger
subset
innat
immun
receptor
recogn
foreign
dna
tolllik
receptor
recogn
dna
unmethyl
cpg
motif
foreign
rna
tlr
rigi
pkr
oa
other
import
understand
basi
immun
respons
strategi
evad
employ
synthet
nucleic
acid
mammalian
system
mani
receptor
bind
respond
highli
structur
self
rna
mixtur
endogen
chemic
modif
strategi
compartment
help
restrict
respons
albeit
alway
success
critic
consid
potenti
immun
respons
design
interpret
sirna
experi
appear
earli
sirna
success
particularli
treat
viral
infect
may
larg
unrecogn
immun
compon
one
typic
consid
innat
immun
respons
synthet
nucleic
acid
undesir
ote
circumst
immun
stimul
may
benefici
could
exploit
therapeut
number
excel
review
import
subject
publish
reader
refer
recent
work
judg
maclachlan
robbin
et
al
krieg
hennessi
et
al
spite
exist
mani
public
demonstr
import
immun
effect
surprisingli
larg
percentag
vivo
studi
seem
ignor
problem
includ
mani
manuscript
discuss
present
review
reader
advis
consid
evalu
vivo
rnai
work
variou
receptor
perform
surveil
innat
immun
system
bind
dsrna
bind
singlestrand
rna
three
receptor
detect
synthet
sirna
due
primari
local
endosom
compart
receptor
readili
recogn
bind
ligand
intern
sirna
complex
cation
lipid
polym
mode
deliveri
electropor
hydrodynam
deliveri
peptid
transduct
bypass
transit
compart
often
evad
detect
receptor
likewis
shrna
endogen
synthes
within
cell
viral
templat
less
like
trigger
interferon
respons
sequenc
chemic
synthes
exogen
transfect
lipidbas
reagent
sever
cytoplasm
local
receptor
recogn
foreign
rna
includ
pkr
oa
rigi
fortun
receptor
primarili
recogn
dsrna
longer
tradit
sirna
pkr
oa
differ
end
structur
standard
sirna
exampl
rigi
recogn
end
gener
vivo
viral
replic
vitro
transcript
product
trigger
structur
present
mammalian
mrna
rigi
may
also
activ
blunt
end
longer
dsrna
strategi
exist
enabl
synthet
sirna
evad
detect
innat
immun
system
design
chemic
modif
mention
receptor
preferenti
recogn
long
rna
better
short
rna
sirna
design
employ
shorter
sequenc
asymmetr
sirna
gener
lower
risk
trigger
immun
respons
longer
sequenc
dsirna
long
dsrna
natur
exist
within
mammalian
cell
usual
elicit
immun
respons
achiev
compartment
exclus
rna
endosom
tlr
endogen
chemic
modif
sugar
modif
rna
base
modif
pseudouridin
common
mammalian
trna
rrna
help
larg
highli
structur
speci
evad
initi
autoimmun
respons
contrast
foreign
rna
viral
rna
exogen
synthet
speci
bear
modif
typic
trigger
immun
respons
variou
chemic
modif
employ
help
synthet
sirna
evad
immun
detect
rna
commonli
use
natur
occur
rna
variant
rel
inexpens
also
improv
nucleas
stabil
extens
modif
necessari
fewer
residu
modifi
still
block
immun
respons
furthermor
sirna
function
competit
antagonist
act
ci
tran
retain
inhibitori
efficaci
dose
either
singleor
dsrna
fact
sirna
block
activ
induc
small
molecul
agonist
loxoribin
lna
also
help
evad
immun
detect
critic
evalu
work
done
use
sirna
vivo
variou
complic
aris
immun
respons
import
keep
basic
fact
mind
studi
done
vitro
employ
cell
line
hela
express
support
conclus
compound
investig
immunostimulatori
potenti
ideal
vitro
studi
perform
use
mix
popul
primari
immun
cell
fresh
peripher
blood
mononuclear
cell
importantli
sign
immun
activ
test
vivo
import
look
immun
activ
hour
postadministr
catch
earli
late
phase
respons
studi
examin
cytokin
level
look
activ
inflammatori
pathway
gene
hour
easili
miss
import
sign
immun
stimul
whole
anim
imag
report
system
challeng
system
use
sirna
anim
wellknown
nucleas
instabl
poor
bioavail
lack
tissuetarget
issu
associ
pharmacokinet
pk
pharmacodynam
pd
cumul
repres
signific
hurdl
therapeut
applic
technolog
sirna
sequenc
mediat
potent
knockdown
gene
interest
readili
obtain
today
reason
emphasi
develop
suitabl
deliveri
vehicl
make
function
sirna
avail
desir
tissu
mani
vivo
sirna
studi
done
without
therapeut
target
object
character
capabl
variou
deliveri
system
studi
pkpd
positron
emiss
tomographi
pet
singlephoton
emiss
comput
tomographi
spect
imag
technolog
appli
defin
pk
biodistribut
sirna
nanoplex
use
wholeanim
imag
modal
benefici
measur
requir
anim
sacrific
harvest
tissu
biochem
assay
rather
assay
method
allow
facil
rapid
quantit
serial
data
collect
cohort
anim
extend
time
cours
sever
proofofprincipl
experi
done
use
pet
spect
imag
inject
sirna
first
exampl
sirna
biodistribut
follow
iv
administr
balbc
mice
measur
dual
isotop
spect
inlabel
sirna
tclabel
bone
anatom
orient
found
correl
reliabl
result
obtain
tissu
harvest
scintil
count
dissect
tissu
next
pk
inlabel
free
sirna
compar
polyethyleneimin
pei
complex
sirna
two
formul
show
differ
distribut
pattern
hour
follow
iv
administr
time
peicomplex
sirna
show
significantli
greater
accumul
stomach
compar
free
sirna
key
find
endpoint
data
free
sirna
peisirna
wellcorrel
assay
either
spect
tissu
harvest
follow
scintil
count
find
result
use
assay
valid
use
wholeanim
spect
viabl
method
sirna
quantif
positronemit
isotop
f
conjug
sirna
use
pet
imag
dynam
quantit
pet
imag
perform
follow
iv
administr
flabel
sirna
rat
indic
nativ
rapidli
elimin
renal
excret
minut
respect
sirna
slightli
higher
bioavail
none
modifi
sirna
show
signific
luciferas
knockdown
xenograft
tumor
model
express
report
gene
gari
colleagu
also
use
pet
imag
compar
sirna
uptak
murin
tumor
model
via
polyethyleneglycolconjug
pegyl
polyplex
poli
dimethylaminoethyl
methacryl
pdmaema
pegyl
micelleplex
triblock
copolym
biodistribut
analysi
show
predomin
remain
signal
gastrointestin
tract
gall
bladder
inject
dose
seen
tissu
deliveri
system
micelleplex
sirna
show
slightli
higher
tissu
retent
lung
tumor
tissu
compar
polyplex
sirna
like
result
larger
particl
size
summari
pet
imag
use
method
noninvas
quantifi
biodistribut
pk
sirna
deliveri
result
studi
underscor
import
function
deliveri
system
ivadminist
sirna
mudd
colleagu
recent
report
pk
studi
suggest
tissuespecif
target
could
achiev
use
sirnacontain
dynam
polyconjug
dpc
group
employ
hybrid
pet
plu
comput
tomographi
ct
imag
method
gain
insight
synthet
sirna
deliveri
system
compon
deliveri
system
sirna
stabil
psmodif
endosomolyt
amphipath
polym
butyl
amino
vinyl
ether
modifi
cuchel
dota
subsequ
label
positronemit
isotop
cu
ct
contrast
agent
exia
employ
accur
defin
liver
expect
free
sirna
administ
iv
mice
rapidli
clear
inject
dose
lost
urin
minut
petct
imag
show
percent
inject
dose
sirnapolym
complex
accumul
liver
minut
total
accumul
sirnadpc
liver
cours
hour
follow
iv
administr
polymeralon
slower
onset
accumul
inject
dose
appear
liver
hour
bioluminesc
imag
bli
commonli
use
quantifi
luciferas
express
report
system
whole
anim
oppos
pk
sirna
nanoplex
measur
pet
bli
provid
reliabl
assay
system
quantifi
function
sirna
vivoor
assess
pd
work
davi
lab
combin
imag
modal
character
pk
pd
sirna
deliveri
employ
pet
track
biodistribut
culabel
sirna
deliv
iv
administr
complex
cyclodextrinbas
nanoparticl
sirna
shown
rapidli
accumul
kidney
subsequ
bladder
excret
true
transferrin
tf
target
polyplex
contain
target
ligand
tumor
local
measur
pet
target
versu
nontarget
polyplex
also
quit
similar
bli
use
quantifi
luciferas
knockdown
constitut
express
murin
tumor
model
function
tftarget
sirna
improv
compar
nontarget
formul
suggest
tftarget
ligand
enabl
receptormedi
endocytosi
promot
intern
necessari
sirna
function
work
bartlett
davi
compar
pd
chemic
modifi
sistabl
sirna
unmodifi
sirna
follow
hydrodynam
tail
vein
administr
mice
improv
knockdown
luciferas
activ
liver
seen
use
modifi
duplex
mathemat
model
data
suggest
main
advantag
use
modifi
sirna
occur
uptak
cell
sirna
intracellular
kinet
predict
significantli
affect
chemic
modif
calando
pharmaceut
pasadena
ca
use
bli
screen
sirna
vivo
efficaci
subunit
ribonucleotid
reductas
lead
sirna
sequenc
target
identifi
vitro
screen
sirna
mgkg
coadminist
via
hydrodynam
dose
plasmid
express
fusion
protein
mg
kg
luciferas
express
liver
observ
via
bli
cours
day
compar
control
dose
plasmid
alon
plasmid
plu
control
sirna
sirna
show
knockdown
day
day
valu
similar
hydrodynam
coadministr
report
plasmid
control
sirna
target
luciferas
studi
also
serv
demonstr
bli
use
assay
valid
efficaci
sirna
vivo
one
challeng
use
bli
assay
pd
system
deliv
sirna
achiev
stabl
consist
luciferas
express
target
tissu
interest
svensson
colleagu
develop
mous
ubiquit
express
luciferas
via
cremedi
recombin
remov
stop
codon
allel
demonstr
stabl
uniform
luciferas
express
tissu
new
flash
mous
abl
show
luciferas
knockdown
via
novel
lipidoid
compound
alnylam
pharmaceut
cambridg
formul
sirna
specif
luciferas
gene
sirna
dose
iv
mgkg
pyrimidin
sens
strand
termin
psmodifi
strand
luciferas
level
evalu
hour
bli
demonstr
decreas
luminesc
compar
control
anim
dose
sirna
target
factor
vii
knockdown
observ
liverspecif
type
anim
model
could
facilit
rapid
highthroughput
screen
deliveri
system
sirna
deliveri
similar
improv
luciferaseexpress
mous
scientist
sirna
develop
mous
model
liverspecif
luciferas
express
induc
livertarget
adenoassoci
viru
aav
express
recombin
cre
group
systemat
studi
anim
time
cours
luciferas
knockdown
liver
use
variou
dose
lipid
nanoparticleformul
sirna
addit
pd
effect
author
quantifi
total
amount
sirna
liver
fraction
sirna
time
point
durat
studi
demonstr
direct
relationship
luciferas
mrna
protein
sirna
howev
total
sirna
level
liver
vast
abund
correl
well
luciferas
knockdown
suggest
guid
strand
load
ratedetermin
step
vivo
rnai
model
tissuespecif
luciferas
express
advantag
influenc
background
express
neighbor
tissu
bli
use
combin
hydrodynam
inject
luciferas
plasmid
achiev
substanti
express
liver
also
serv
model
assess
sirnamedi
knockdown
vivo
asid
bioluminesc
whole
anim
fluoresc
imag
detect
presenc
nearinfrar
nir
dye
mammalian
tissu
fluoresc
use
compar
distribut
pattern
cholesteroland
rgdconjug
result
studi
pk
suggest
liveraccumul
sirna
readili
elimin
via
gall
bladder
small
intestin
previous
observ
novel
elimin
pathway
valid
follow
bile
duct
ligat
block
appear
fluoresc
gastrointestin
tract
also
work
yagi
colleagu
demonstr
sirna
formul
cation
lipid
complex
could
deliv
system
mice
bear
sc
tumor
fluoresc
observ
tumor
tissu
day
postinject
function
sirna
target
inhibit
tumor
angiogenesi
show
reduct
tumor
volum
day
follow
iv
dose
day
xiong
lavasanifar
recent
describ
multifunct
micel
deliveri
system
sirna
incorpor
poli
ethylen
oxid
poli
function
either
poli
ethylen
amin
doxorubicin
addit
polymer
backbon
coupl
rgd
tat
peptid
upon
assembl
polymerpeptid
micellar
shell
surround
doxorubicin
sirna
label
deliveri
vehicl
well
label
sirna
enabl
wholeanim
nir
imag
demonstr
compon
coloc
multidrug
resist
tumor
xenograft
mice
tumor
local
depend
presenc
rgd
peptid
target
particular
studi
proofofprincipl
deliveri
experi
stop
short
demonstr
increas
chemotherapeut
efficaci
gain
doxorubicin
deliveri
coupl
knockdown
wholeanim
imag
experi
discuss
point
employ
iv
dose
whole
anim
imag
techniqu
also
use
studi
intraperiton
ip
dose
sirna
huang
colleagu
use
ct
bli
noninvas
assess
pd
lipidoid
nanoparticl
murin
model
ovarian
cancer
tumorbear
mice
ipdos
sirna
target
formul
lipidoid
mice
dose
twice
weekli
cours
week
mice
show
increas
ovarian
cancer
tumor
load
week
tumor
grew
fivefold
volum
treat
nontarget
sirna
measur
microct
way
luciferaseexpress
mous
tumor
model
use
demonstr
formul
dose
regimen
show
signific
increas
tumor
volum
cours
week
measur
bli
mice
untreat
treat
nontarget
sirna
surviv
durat
experi
due
rapidli
increas
tumor
volum
abbott
lab
report
develop
novel
positivereadout
assay
system
monitor
pd
sirna
deliveri
vehicl
tet
repressor
tetr
protein
bind
tet
operon
promot
sequenc
tetr
homodim
block
promot
function
prevent
express
link
gene
suppress
tetr
remov
block
allow
express
case
either
luciferas
gene
potent
sirna
valid
tetr
success
deliveri
duplex
cell
bear
tetrreport
transgen
result
appear
detect
signal
report
positivereadout
report
system
use
test
effici
sirna
deliveri
sever
common
lipid
polymer
system
interestingli
upon
test
combin
deliveri
system
rout
deliveri
dimethylamino
propan
dodap
base
liposom
stabl
nucleic
acid
lipid
particl
snalp
gave
posit
readout
iv
dose
mgkg
dose
twice
target
liver
tumor
novel
report
system
greatli
reduc
background
signal
ubiquit
express
tetr
report
gene
allow
pd
assay
tissuespecif
manner
vitro
pkpd
assay
quantit
revers
transcript
pcr
rtqpcr
sensit
robust
method
quantifi
mrna
harvest
tissu
assess
pd
sirna
polyplex
sinc
mrna
endogen
biomolecul
target
sirna
assay
relev
proofofprincipl
deliveri
experi
determin
mrna
level
much
direct
measur
sirna
function
phenotyp
readout
usual
employ
mous
model
particular
diseas
state
howev
recent
manuscript
identifi
potenti
artifact
encount
use
rtqpcr
vivo
sampl
high
dose
sirna
given
local
tissu
sirna
guid
strand
retain
isol
cellular
rna
qpcr
assay
primer
flank
sirna
target
site
retain
guid
strand
inhibit
revers
transcript
rt
reaction
lesser
extent
qpcr
result
fals
posit
result
ie
incorrectli
observ
reduc
level
target
gene
interest
rtqpcr
wide
use
method
quantifi
knockdown
mediat
sirna
recent
report
biodistribut
kinet
lipid
nanoparticl
deliveri
system
use
stemloop
rtqpcr
quantifi
amount
sirna
variou
tissu
follow
iv
administr
mgkg
via
tail
vein
organ
accumul
sirna
greatest
liver
spleen
kidney
wherea
duodenum
lung
heart
brain
show
minim
accumul
fluoresc
microscopi
tissu
section
show
similar
biodistribut
result
sirna
contain
label
passeng
strand
author
use
immunofluoresc
stain
character
uptak
differ
cell
type
within
liver
lnpsirna
deliv
kupffer
cell
hepatocyt
timedepend
manner
consider
uptak
kupffer
cell
may
warrant
greater
attent
clearanc
mononuclear
phagocyt
system
liver
may
play
import
role
especi
sirna
administ
iv
rapid
amplif
clone
end
definit
method
confirm
mrna
cleavag
occur
via
mechan
action
follow
sirna
transfect
protocol
place
oligonucleotid
linker
newli
form
mrna
follow
cleavag
mediat
risc
cleavag
occur
precis
base
sirna
guid
strand
linker
provid
forward
pcr
primer
bind
site
pcr
done
use
genespecif
revers
primer
locat
cut
site
demonstr
exist
cleavag
product
precis
locat
diagnost
mrna
cleavag
occur
via
rnai
mechan
action
note
howev
show
posit
result
exclud
possibl
coexist
immun
ote
may
still
contribut
observ
phenotyp
judg
colleagu
use
demonstr
cleavag
target
regress
tumor
mice
treat
sirna
deliv
snalp
use
rna
isol
treat
tumor
cell
rt
perform
use
genespecif
primer
follow
pcr
result
amplicon
expect
size
sequenc
amplicon
confirm
posit
cleavag
site
cleav
sequenc
found
tumor
mice
treat
sirna
found
mice
treat
nontarget
control
sirna
employ
mani
investig
part
evalu
sirna
experi
perform
vivo
gold
standard
identifi
rnai
mechan
action
system
deliveri
iv
administr
iv
administr
gener
effect
way
achiev
system
deliveri
larg
molecul
drug
nucleic
acid
serum
rel
hostil
environ
variou
protein
nucleas
present
circul
requir
sirna
protect
deliveri
system
andor
chemic
modif
ideal
deliveri
system
also
includ
type
target
compon
lead
preferenti
accumul
sirna
organtissu
interest
compar
local
deliveri
iv
dose
requir
significantli
larger
amount
sirna
order
achiev
bioavail
site
action
especi
absenc
target
ligand
varieti
differ
strategi
employ
tri
achiev
goal
liposom
lipidbas
nanoparticl
liposom
lipid
nanoparticl
commonli
employ
deliv
sirna
vivo
sirna
formul
liposom
sever
commerci
sourc
proprietari
lipid
composit
likewis
use
dioleoylphosphotidylethanolamin
dope
trimethylammonium
propan
dotap
cholesterol
form
cation
liposom
via
solventemuls
method
commonli
use
gener
formul
particl
toxic
vehicl
limit
varieti
differ
chemic
modif
strategi
employ
mitig
problem
blunt
design
sirna
clinic
trial
part
silenc
therapeut
program
sirna
target
protein
kinas
formul
lipid
nanoparticl
studi
use
iv
administr
two
mous
model
induc
lung
metastasi
lipid
previous
shown
target
vascular
endothelium
mechan
action
like
vascular
tumor
cell
tail
vein
inject
either
melanoma
cell
lewi
lung
carcinoma
cell
result
rapid
tumor
growth
lung
good
model
metastat
diseas
mice
treat
mgkg
begin
one
day
tumor
cell
inject
dose
iv
everi
day
day
day
mean
lung
weight
mice
less
half
neg
control
group
treatment
vehicl
dose
mmoll
sucros
control
sirnalipid
formul
upon
macroscop
evalu
signific
reduct
tumor
colon
lung
model
induc
metastasi
yokota
colleagu
report
studi
nonhuman
primat
treat
hepat
viru
gb
virusb
flaviviru
model
hepat
c
viru
infect
unmodifi
sirna
target
gbvb
formul
cation
lipid
dose
iv
mgkg
daili
day
viral
titer
undetect
antigbvb
sirnatr
cohort
howev
administr
mgkg
dose
control
sirna
also
suppress
viral
load
evalu
interferon
level
suggest
may
nonspecif
respons
immun
system
reduc
gbvb
level
induct
much
lower
antigbvbdos
group
taken
indic
iv
dose
cation
liposomeformul
sirna
induc
interferon
respons
yet
antigbvb
sirna
still
mediat
targetspecif
knockdown
infect
viru
infecti
diseas
oncolog
indic
may
area
sirna
use
combin
effect
immun
stimul
plu
specif
gene
target
knockdown
could
combin
give
improv
result
either
effect
alon
use
arthriti
model
system
unmodifi
sirna
target
tnf
deliv
iv
inject
mice
use
formul
dope
combin
cation
lipid
weekli
administr
formul
sirna
led
signific
decreas
tumor
necrosi
factor
tnf
level
measur
elisa
result
complet
regress
induc
arthriti
work
later
expand
includ
formul
sirna
target
wherein
weekli
dose
regimen
mgkg
improv
reduct
rheumatoid
arthriti
patholog
featur
greater
extent
antitnf
sirna
monotherapi
deliveri
psmodifi
sirna
lung
demonstr
methoxypolyethylen
glycol
mpeg
function
lipopolyamin
staramin
deliveri
system
follow
iv
administr
sirna
biodistribut
studi
show
lung
retain
greatest
amount
sirna
hour
compar
liver
kidney
spleen
per
gram
tissu
basi
staramin
function
monodispers
mpeg
da
oppos
polydispers
form
improv
lung
target
attempt
identifi
lung
cell
type
target
ivdos
nanocomplex
author
demonstr
knockdown
endotheli
cellspecif
transcript
tek
deliveri
system
wherea
knockdown
epitheli
cell
fibroblastor
leukocytespecif
target
absent
snalp
tekmira
pharmaceut
burnabi
british
columbia
canada
formerli
protiva
biotherapeut
employ
multipl
studi
deliv
sirna
vivo
hepat
target
first
larg
vivo
studi
perform
use
snalp
report
morrissey
colleagu
unmodifi
modifi
sirna
compar
efficaci
reduc
hepat
b
viru
infect
use
cation
lipid
nanoparticl
system
unmodifi
sirna
provok
strong
immun
respons
highli
modifi
sirna
includ
dna
ps
bond
well
toler
without
aid
deliveri
tool
circul
halflif
unmodifi
sirna
minut
increas
hour
use
highli
modifi
sirna
formul
snalp
mice
given
dose
mgkg
daili
day
saw
fold
reduct
detect
hepat
b
viru
dna
level
presenc
residu
later
identifi
primari
modif
block
immun
respons
sirna
deliv
use
cation
lipid
vehicl
especi
uridin
base
snalp
vehicl
employ
first
studi
sirna
deliv
nonhuman
primat
chemic
modifi
antiapob
sirna
similar
version
previous
report
suppress
apob
express
rodent
use
cholesterol
deliveri
approach
administ
iv
cynomolgu
monkey
dose
mgkg
reduct
apob
mrna
level
seen
follow
singl
mgkg
dose
repres
fulli
increas
potenc
efficaci
observ
rat
use
cholesterolmedi
deliveri
higher
dose
signific
reduct
serum
cholesterol
observ
sustain
least
day
follow
end
treatment
rnai
mechan
action
confirm
demonstr
expect
cutsit
apob
mrna
use
techniqu
treatment
well
toler
studi
wide
view
valid
sirna
compound
might
suitabl
drug
develop
human
maclachlin
colleagu
studi
use
combin
sirna
snalp
potenti
antitumor
therapi
sirna
modifi
administ
iv
dose
mgkg
treatment
reduc
growth
induc
apoptosi
xenogen
human
tumor
cell
implant
liver
nude
mice
syngen
tumor
cell
implant
liver
immunecompet
aj
mice
evalu
serum
cytokin
level
confirm
absenc
immun
respons
sirna
snalp
targetspecif
cleavag
mrna
demonstr
use
racepcr
confirm
rnai
mechan
action
separ
oncolog
studi
involv
anoth
cellcycl
protein
demonstr
effect
snalp
system
deliv
sirna
orthotop
tumor
model
hepatocellular
carcinoma
gener
human
cell
four
dose
mgkgdose
snalpformul
sirna
target
given
iv
cours
day
bli
use
monitor
tumor
growth
luciferas
signal
obtain
lower
mice
receiv
sirna
compar
cohort
receiv
neg
control
sirna
target
sirna
formul
snalp
also
develop
therapi
infect
hemorrhag
fever
virus
like
zair
ebola
viru
follow
pilot
studi
guinea
pig
geisbert
colleagu
report
good
result
use
antiebola
sirna
prevent
death
nonhuman
primat
postexposur
lethal
dose
zair
ebola
viru
cocktail
three
sirna
target
zair
ebola
viru
l
polymeras
viral
protein
viral
protein
administ
macaqu
monkey
mgkg
iv
infus
minut
daili
day
postexposur
viru
anim
given
dose
regimen
surviv
infect
anim
given
fewer
dose
show
mix
respons
offer
first
hope
treatment
diseas
otherwis
show
high
mortal
rate
improv
lipidbas
formul
ongo
anderson
langer
lab
describ
use
combinatori
librari
creat
novel
lipid
composit
test
highthroughput
fashion
improv
characterist
nucleic
acid
deliveri
aid
promis
new
candid
call
lipidoid
found
perform
vivo
test
mice
rat
cynomolgu
monkey
addit
improv
result
nanoparticl
formul
ed
valu
mgkg
cynomolgu
monkey
use
sirna
specif
transthyretin
ttr
gene
target
interest
one
form
human
amyloidosi
use
differ
approach
sempl
colleagu
use
ration
design
strategi
specif
alter
properti
lipid
use
earlier
gener
snalp
creat
lipid
particl
use
dimethylaminopropan
dlindma
analog
search
compound
improv
properti
sirna
deliveri
one
variant
show
particularli
favor
behavior
test
perform
mice
nonhuman
primat
contrast
earlier
gener
lipid
particl
perform
mice
show
ed
low
mgkg
cynomolgu
monkey
low
mgkg
least
tenfold
improv
previou
best
result
new
highli
potent
lipid
formul
primarili
target
liver
find
formul
provid
similar
high
potenc
deliveri
tissu
remain
area
activ
investig
nanoparticl
recent
shown
mediat
gene
silenc
splenic
antigenpres
cell
apc
biodistribut
studi
follow
iv
administr
sirna
deliv
lipid
nanoparticl
demonstr
uptak
liver
note
well
apc
spleen
periton
caviti
addit
mice
dose
lnp
mgkg
contain
sirna
target
gapdh
apc
harvest
western
analysi
show
gapdh
express
decreas
rel
neg
control
sirna
cell
popul
silenc
confirm
rnaimedi
specif
lnp
apc
shown
depend
nanoparticl
sizea
variabl
control
ratio
lipid
compon
specif
nm
lnp
target
sirna
hepatocyt
well
apc
wherea
nm
lnp
show
mark
decreas
rnai
liver
maintain
potenc
apc
relat
studi
lnp
use
iv
deliv
sirna
target
inflammatori
monocyt
fluoresc
molecular
tomographyct
use
biodistribut
imag
lnp
contain
sirna
label
mgkg
show
peak
fluoresc
spleen
per
gram
tissu
basi
analysi
use
flow
cytometri
specif
identifi
splenic
high
monocyt
highest
uptak
rnaimedi
knockdown
high
monocyt
confirm
qpcr
western
blot
mice
treat
ivdos
lnp
dose
schedul
mgkg
day
day
importantli
knockdown
result
greatli
decreas
migrat
high
monocyt
led
decreas
accumul
site
infect
given
biweekli
dose
regimen
mgkgday
specif
decreas
advers
function
monocyt
observ
mous
model
atherosclerot
plaqu
coronari
arteri
occlus
pancreat
islet
transplant
tumor
volum
adami
colleagu
marina
biotech
recent
describ
synthesi
novel
lipidbas
amphoter
nanoparticl
deliveri
system
base
dialkyl
arginin
dila
compound
final
optim
particl
nm
diamet
undergo
phdepend
phase
transit
assist
escap
particl
endosom
cytoplasm
follow
iv
inject
particl
rapidli
clear
halflif
minut
mice
becom
undetect
hour
postinject
uptak
primarili
hepat
follow
spleen
kidney
lung
jejunum
uptak
detect
skelet
muscl
use
antiapob
sirna
ed
mgkg
observ
mrna
suppress
liver
mice
deliveri
tool
also
use
good
result
bladder
employ
local
administr
approach
see
liposom
lipid
nanoparticl
also
conjug
target
ligand
improv
alter
biodistribut
tissuetarget
pattern
sato
colleagu
conjug
vitamin
liposom
mean
improv
deliveri
hepat
stellat
cell
treat
hepat
fibrosi
follow
chemic
injuri
liposom
made
use
lipotrust
reagent
system
contain
diethanolamin
chlorid
cholesterol
dope
vitamin
aconjug
liposom
load
sirna
target
collagen
chaperon
heat
shock
protein
gene
administ
iv
dose
mgkg
two
three
time
weekli
vitamin
aderivat
liposom
sirna
reduc
collagen
secret
hepat
stellat
cell
prevent
fibrosi
subsequ
cirrhosi
rat
treat
chemic
toxin
dimethylnitrosamin
carbon
tetrachlorid
bile
duct
ligat
peer
colleagu
describ
antibodybas
approach
produc
target
lipid
nanoparticl
carrier
sirna
research
tradit
favor
use
pegbas
coat
provid
stealth
charact
nanoparticl
group
employ
hyaluronan
natur
occur
biopolym
mammal
gener
immun
respons
minim
toxic
sirna
condens
protamin
complex
shell
made
neutral
lipid
hyaluronan
attach
via
dipalmitoylphosphatidylethanolamin
dppe
target
provid
coval
attach
monoclon
antibodi
specif
integrin
cell
surfac
marker
express
mononuclear
leukocyt
final
particl
call
itsnp
carri
sirna
molecul
cargo
equat
sirna
per
attach
surfac
antibodi
molecul
itsnp
load
control
sirna
sirna
target
cyclin
import
cell
cycl
regul
essenti
cell
divis
leukocyt
receiv
sirna
via
itsnp
show
impair
prolifer
therebi
limit
potenti
mount
immun
respons
system
use
treat
mous
model
inflammatori
bowel
diseas
dextran
sulfateinduc
coliti
dsscoliti
control
itsnp
administ
iv
dose
mgkg
everi
day
total
four
dose
treatment
reduc
level
express
mrna
encod
inflammatori
cytokin
tnf
gut
immunosuppress
cytokin
sirnatr
anim
show
mark
reduct
gut
inflamm
tissu
damag
less
weight
loss
improv
hematocrit
compar
control
anim
studi
mechan
uptak
sirna
formul
lipid
nanoparticl
akinc
colleagu
found
pathway
vari
certain
characterist
lipid
specif
apolipoprotein
e
apo
found
play
signific
role
uptak
ioniz
lipid
nanoparticl
cation
lipid
nanoparticl
incorpor
nacetylgalactosamin
galnac
lipid
nanoparticl
result
bind
uptak
mediat
hepat
asialoglycoprotein
receptor
without
apo
lowdens
lipoprotein
ldl
receptor
depend
clinic
trialsliposom
lipid
particl
iv
sever
clinic
trial
complet
current
progress
use
previous
discuss
lipid
formul
employ
iv
administr
tekmira
pharmaceut
formerli
protiva
biotherapeut
open
phase
doseescal
trial
http
june
evalu
snalpdeliv
antiapob
sirna
patient
hypercholesterolemia
program
call
tkmapob
total
patient
enrol
trial
receiv
singl
dose
snalpformul
spite
extens
prior
test
formul
rodent
nonhuman
primat
littl
evid
immunostimulatori
potenti
one
two
patient
receiv
highest
dose
develop
flulik
symptom
indic
develop
signific
innat
immun
respons
trial
stop
resum
pend
reformul
snalp
carrier
sirna
cargo
limit
likelihood
recurr
immunerel
side
effect
addit
tekmira
pharmaceut
phase
trial
recruit
stage
doseescal
sirna
target
deliv
patient
solid
tumor
http
tekmira
pharmaceut
hope
file
ind
us
food
drug
administr
begin
phase
trial
antiebola
sirna
tkmebola
alnylam
pharmaceut
initi
phase
doseescal
trial
pair
snalpformul
sirnabas
drugsboth
recruit
phase
first
openli
recruit
particip
drug
contain
sirna
target
vegf
treatment
solid
tumor
http
result
trial
recent
discuss
june
meet
american
societi
clinic
oncolog
http
abstractascoorg
total
patient
given
dose
rang
mgkg
dose
per
patient
drug
safeti
profil
deem
accept
alnylam
recommend
mgkg
dose
everi
week
efficaci
evalu
plan
phase
ii
trial
second
current
inact
phase
trial
would
expand
number
patient
enrol
studi
http
anoth
drug
target
ttr
hepatocyt
treatment
ttrmediat
amyloidosi
http
clinicaltri
antittr
sirna
formul
snalp
partnership
tekmira
pharmaceut
particip
still
recruit
trial
open
juli
second
program
diseas
develop
alnylam
parallel
employ
differ
lipid
formul
compound
still
preclin
phase
silenc
therapeut
target
solid
tumor
lipidformul
atuplex
sirna
http
studi
open
result
trial
recent
discuss
june
asco
meet
http
favor
safeti
profil
report
doselimit
toxic
obviou
evid
cytokin
activ
singlepati
phase
safeti
studi
sponsor
univers
duisburgessen
test
administr
sirna
anion
lipid
formul
unmodifi
sirna
target
fusion
oncogen
bcrabl
deliv
dose
patient
previous
receiv
allogen
hematopoiet
stem
cell
transplant
imatinibresist
chronic
myeloid
leukemia
sirna
treatment
coupl
iv
plu
sc
dose
initi
day
follow
transplant
therapi
result
detect
inhibit
bcrabl
led
chronic
myeloid
leukemia
cell
apoptosi
without
associ
advers
effect
could
ascrib
sirna
drug
polyplex
deliveri
system
sever
nonlipid
cation
polym
use
system
deliv
sirna
due
complic
caus
electrostat
interact
posit
charg
nanoparticl
neg
charg
serum
protein
improv
perform
cation
lipid
cation
polyplex
formul
usual
seen
conjug
uncharg
hydrophil
group
peg
creat
stealth
coat
help
prevent
bind
clump
serum
protein
administ
iv
accumul
cation
nanoparticl
lead
microns
aggreg
becom
lodg
capillari
bed
trigger
complement
cascad
inflammatori
respons
especi
lung
pei
cation
polym
wide
use
nucleic
acid
deliveri
due
abil
condens
dna
rna
well
abund
protonat
secondari
amin
thought
aid
endosom
escap
via
proton
spong
effect
although
unmodifi
pei
toxic
newer
gener
chemicallyalt
peibas
vehicl
wide
use
vivo
deliveri
tool
suggest
mitochondri
membran
depolar
basi
much
observ
peirel
toxic
progress
use
pei
deriv
deliveri
tool
sirna
recent
review
gunther
colleagu
kamlah
colleagu
employ
commerci
avail
product
jetpei
polyplu
linear
pei
deriv
unmodifi
sirna
target
complex
pei
reagent
n
p
ratio
deliv
iv
sirna
per
dose
mgkg
mice
bear
lewi
lung
carcinoma
implant
surviv
prolong
combin
therapi
marker
found
markedli
reduc
sirnatr
anim
control
anim
author
also
attempt
rout
deliveri
includ
peisirna
dose
ip
peiand
lipofectaminesirna
dose
intratrach
lipofectaminesirna
dose
iv
use
sirna
demonstr
peicondens
sirna
dose
iv
effici
target
pulmonari
tumor
implant
uncertain
nonspecif
effect
relat
aforement
nanoparticl
aggreg
lung
capillari
entrap
contribut
find
work
buhjwalla
colleagu
employ
pei
chief
condensingag
sirna
novel
bioconjug
nanoparticl
nanoplex
contain
pegpeicondens
sirna
target
chka
gdlabel
polyllysin
prodrugactiv
enzym
cytosin
deaminas
sirnaand
proteincontain
nanoplex
dose
iv
tumorbear
mice
mgkg
entir
nanoplex
dose
iv
hour
follow
inject
nanoplex
allow
suffici
time
particl
accumul
tumor
tumor
doubl
time
variou
treatment
group
day
neg
control
anim
day
anim
receiv
sirnananoplex
alon
day
receiv
enzymeprodrug
alon
day
receiv
sirnananoplexenzymeprodrug
combin
therapi
combin
therapi
sirna
target
chka
prodrug
convert
activ
drug
significantli
decreas
tumor
progress
poli
amidoamin
pamam
dendrim
form
nanoplex
sirna
via
electrostat
interact
much
like
pei
recent
publish
result
describ
effect
follow
iv
administr
pamam
dendrim
complex
cocktail
dsirna
combinatori
deliveri
dsirna
target
tatrev
viral
transcript
well
host
transcript
human
mice
infect
weekli
antivir
treatment
mgkg
total
dsirna
began
week
postinfect
continu
week
viral
load
monitor
qpcr
mice
dose
dsirna
cocktailpamam
deliveri
system
display
viral
load
reduc
approxim
three
order
magnitud
compar
variou
neg
control
preliminari
work
confirm
target
knockdown
mediat
sitedepend
manner
experi
demonstr
rebound
viral
titer
could
ablat
retreat
week
postinfect
complet
suppress
continu
week
biodistribut
dsirna
via
pamam
nanoplex
confirm
peripher
blood
mononuclear
cell
well
liver
demonstr
obviou
toxic
polym
success
employ
construct
sirnananoparticl
includ
chitosan
polypeptid
cyclodextrin
chitosan
natur
product
deriv
crustacean
shell
linear
cation
polysaccharid
made
deacetyl
chitinpolymer
nacetylglucosamin
linkag
one
recent
studi
imidazolemodifi
chitosan
incorpor
pegyl
polyplex
iv
dose
antigapdh
sirna
mice
sirna
dose
formul
mgkg
gave
signific
knockdown
gapdh
protein
lung
liver
compar
imidazolemodifi
chitosan
control
sirna
unmodifi
chitosan
antigapdh
sirna
pill
colleagu
employ
chitosanbas
nanoparticl
deliv
sirna
via
iv
inject
retroorbit
vein
nude
mice
bear
implant
human
breast
carcinoma
cell
line
unmodifi
control
sirna
sirna
target
rhoa
gene
administ
everi
day
day
tumor
growth
antirhoatr
anim
significantli
inhibit
compar
anim
receiv
control
sirna
mgkg
dose
cohort
studi
employ
chitosan
nanoparticl
use
intratrach
ip
deliveri
rout
discuss
section
review
signific
bodi
work
publish
davi
laboratori
calando
pharmaceut
relat
use
cyclodextrincontain
polyc
sirna
deliveri
vehicl
suitabl
vivo
use
iv
deliveri
work
group
well
cover
earlier
review
recent
preclin
trial
nonhuman
primat
doseescal
studi
ivadminist
cyclodextrin
particl
contain
tftarget
ligand
unmodifi
sirna
target
subunit
ribonucleotid
reductas
dose
multipl
time
mgkg
cytokin
assay
show
increas
mgkg
dose
group
sign
immunostimul
treatment
group
receiv
lower
dose
set
experi
defin
optim
dose
schedul
cyclodextrin
nanoparticl
contain
sirna
mgkg
dose
consecut
day
mice
contain
mm
tumor
sc
tftarget
nanoparticl
show
reduc
tumor
volum
day
surviv
mice
extend
significantli
beyond
untreat
mice
margin
beyond
nontarget
treatment
prefer
embodi
cyclodextrin
vehicl
use
first
clinic
trial
sirnapolyplex
formul
administ
iv
human
see
atelocollagen
watersolubl
pepsin
digest
product
collagen
anoth
biopolym
success
use
sirna
deliveri
vehicl
one
studi
sirna
administ
iv
singl
dose
complex
atelocollagen
reduc
symptom
contact
hypersensit
mice
known
initi
inflammatori
respons
associ
contact
hypersensit
studi
earswel
use
function
assay
quantifi
degre
contact
hypersensit
atelocollagenformul
sirna
target
decreas
recruit
immun
cell
result
signific
decreas
earswel
compar
sirna
deliv
use
liposom
kinouchi
colleagu
describ
use
atelocollagen
deliv
unmodifi
sirna
target
myostatin
either
local
intramuscular
im
inject
system
iv
retroorbit
inject
increas
muscl
mass
wildtyp
dmx
mice
model
duchenn
muscular
dystrophi
localand
ivinject
cohort
muscl
mass
myofibril
diamet
increas
suggest
treatment
kind
may
eventu
offer
therapeut
benefit
musclewast
diseas
duchenn
muscular
dystrophi
novel
cellpenetr
peptid
cpp
agyl
lgkinlkalaalallil
contain
steryl
nterminu
multipl
chloroquin
analog
conjug
lysin
posit
polyplex
sirna
target
administ
singl
iv
dose
mgkg
mice
hour
mrna
level
measur
kidney
show
decreas
level
compar
control
sirna
knockdown
lung
similar
observ
kidney
liver
knockdown
even
better
toxic
report
formul
gener
peptid
mediat
cell
uptak
cation
complex
anion
nucleic
acid
form
tight
electrostat
complex
charg
neutral
block
cellpenetr
properti
peptid
reagent
reduc
function
perform
direct
conjug
complex
sirna
peptid
therefor
met
gener
widespread
success
bloodbrain
barrier
bbb
normal
present
obstacl
larg
molecul
drug
entri
central
nervou
system
cn
kumar
colleagu
describ
use
peptid
deliveri
tool
facilit
uptak
ivadminist
sirna
cn
peptid
deriv
rabi
viru
glycoprotein
rvg
fuse
polyarginin
cation
domain
electrostat
complex
sirna
cargo
rvg
specif
bind
nicotin
acetocholin
receptor
sirna
complex
vehicl
shown
deliv
neuron
cell
function
perform
valid
use
iv
administr
antijev
sirna
complex
protect
mice
enceph
caus
infect
jev
flaviviru
strategi
later
employ
deliv
antitnf
sirna
cn
specif
target
microgliamacrophag
cell
also
express
nicotin
acetocholin
receptor
iv
administr
antitnf
complex
protect
neuron
inflamm
follow
administr
bacteri
lipopolysaccharid
although
publish
year
ago
independ
valid
potenti
excit
approach
appear
group
use
synthet
peptid
facilit
transit
bbb
either
small
larg
molecul
drug
follow
iv
administr
remain
intens
area
investig
angiochem
develop
suit
engin
peptid
bind
ldl
receptorrel
highli
express
throughout
cn
direct
transport
natur
ligand
across
bbb
properti
one
peptid
studi
detail
properti
appear
favor
develop
cnsdrug
deliveri
aid
gener
lipoplex
deliveri
polyplex
deliveri
vehicl
share
sever
characterist
typic
employ
cation
polym
condens
nucleic
acid
cargo
similar
submicron
particl
size
often
requir
chemic
modif
pegyl
confer
stealth
characterist
recent
manuscript
describ
use
novel
deliveri
system
quit
differ
rest
class
shahzad
colleagu
formul
sirna
reconstitut
highdens
lipoprotein
hdl
nanoparticl
takenup
scaveng
receptor
overexpress
mani
tumor
cell
alverezerv
colleagu
exploit
endogen
nanovesicl
call
exosom
deriv
dendrit
cell
dc
dc
engin
express
exosom
membran
protein
fuse
rvg
thought
direct
cn
target
see
modifi
exosom
load
ex
vivo
sirna
target
target
receiv
much
attent
potenti
involv
pathophysiolog
alzheim
diseas
load
exosom
inject
iv
normal
mice
success
deliv
cargo
cn
mrna
protein
level
reduc
evid
deliveri
tissu
clinic
trialspolyplex
deliveri
system
iv
sirna
target
complex
amantadinecyclodextrin
vehicl
contain
pegshield
employ
tf
target
ligand
phase
trial
open
calando
pharmaceut
may
patient
solid
tumor
refractori
standard
therapi
http
data
gener
use
rna
obtain
tumor
biopsi
one
treat
patient
demonstr
target
mrna
cleav
expect
locat
provid
first
proof
rnai
mechan
action
human
report
also
signific
repres
first
use
sirna
human
iv
administr
use
synthet
polyplex
deliveri
vehicl
ligandsirna
conjug
nake
deliveri
varieti
differ
ligand
function
group
coval
attach
sirna
direct
deliveri
usual
tissuespecif
fashion
approach
sirna
must
chemic
modifi
confer
suffici
nucleas
resist
surviv
nake
exposur
serum
environ
aptam
highli
fold
singlestrand
nucleic
acid
molecul
conform
bind
target
molecul
high
affin
specif
fashion
similar
antibodi
aptam
employ
facilit
deliveri
sirna
vitro
vivo
rossi
colleagu
describ
develop
aptam
specif
protein
express
surfac
hivinfect
cell
aptam
fuse
dsirna
specif
hiv
tatrev
gene
aptamersirna
chimera
made
use
vitro
transcript
modifi
base
entir
strand
made
rna
purin
pyrimidin
base
unmodifi
rna
complement
hybrid
sirnacompon
fusion
construct
constitut
function
sirna
duplex
final
compound
good
rel
nucleas
stabil
could
surviv
nake
incub
serum
follow
uptak
infect
cell
sirna
cleav
aptam
dicer
result
matur
antitatrev
sirna
suppress
hiv
mrna
rnai
mechan
action
demonstr
studi
perform
use
fusion
molecul
iv
administr
human
mous
model
hiv
infect
although
aptam
alon
antihiv
activ
fusion
product
show
greatest
efficaci
reduc
hiv
viral
titer
sever
log
prevent
declin
tcell
characterist
advanc
hiv
infect
antivir
protect
extend
sever
week
last
dose
mcnamara
giangrand
colleagu
use
aptam
specif
bind
prostatespecif
membran
antigen
psma
express
prostat
cell
mani
prostat
cancer
conjug
sirna
treat
human
prostat
cancer
xenograft
nude
mice
taken
prostat
tumor
line
express
psma
lncap
cell
prostat
tumor
line
express
psma
cell
uptak
led
reduct
express
induc
tumor
cell
apoptosi
studi
direct
intratumor
inject
led
regress
tumor
subsequ
work
demonstr
similar
abil
prevent
growth
psmaexpress
human
prostat
tumor
nude
mice
use
iv
administr
like
lipid
nanoparticl
polyplex
pegyl
chimera
result
improv
circul
halflif
reduc
rate
clearanc
varieti
lipophil
moieti
conjug
sirna
improv
uptak
vivo
best
studi
cholesterol
cholesterol
one
first
ligand
employ
directli
facilit
uptak
sirna
follow
iv
administr
soutschek
colleagu
describ
direct
iv
inject
antiapob
sirna
mice
lower
apob
level
reduc
serum
cholesterol
sirna
employ
modifi
rna
ps
linkag
addit
cholesterol
group
extend
serum
halflif
compar
control
sirna
uptak
primarili
seen
liver
heart
also
detect
kidney
adipos
tissu
lung
although
effect
high
dose
sirna
need
administr
mgkg
daili
day
requir
achiev
reduct
apob
level
similarli
cholesterol
use
improv
uptak
antimirna
oligonucleotid
amo
antagomir
follow
iv
administr
mechanist
cholesterolmodifi
sirna
interact
serum
lipoprotein
particl
uptak
depend
upon
cellular
lipoprotein
transmembran
receptor
ldl
receptor
express
necessari
uptak
ldlassoci
cholesterolsirna
primarili
target
liver
contrast
scaveng
receptor
involv
uptak
hdlassoci
sirna
interestingli
transmembran
protein
also
involv
cholesterolsirna
uptak
gene
product
origin
identifi
essenti
sirna
uptak
caenorhabd
elegan
addit
kuwahara
colleagu
recent
demonstr
role
apo
ldl
receptor
uptak
cholesterolmodifi
sirna
brain
capillari
endotheli
cell
follow
iv
administr
mice
vitamin
e
lipidsolubl
antioxid
found
plasma
mammalian
cell
like
cholesterol
usual
associ
serum
lipoprotein
ldl
receptor
scaveng
receptor
involv
cellular
uptak
interestingli
vitamin
e
first
produc
activ
phosphoramidit
conjug
oligonucleotid
synthesi
use
lipophil
captur
tag
nishina
colleagu
conjug
vitamin
e
dsirna
guid
strand
posit
would
remov
dicer
process
follow
deliveri
cytoplasm
duplex
modifi
use
rna
residu
ps
linkag
suffici
stabil
compound
direct
iv
administr
leav
unmodifi
domain
posit
permit
dicer
cleavag
dose
respons
studi
perform
use
vitamin
emodifi
sirna
target
murin
apob
reduct
apob
mrna
level
measur
liver
singl
iv
administr
ed
mgkg
seen
knockdown
apob
observ
mgkg
dose
vitamin
econjug
sirna
also
success
employ
cn
follow
direct
intraventricular
inject
see
although
desir
set
avoid
immun
stimul
follow
inject
synthet
sirna
activ
immun
system
may
benefici
treat
certain
malign
viral
infect
kortylewski
colleagu
describ
system
singlestrand
dna
oligonucleotid
known
potent
agonist
coval
attach
use
aliphat
linker
dsirna
target
use
treat
mice
metastat
melanoma
model
interest
oncolog
target
upregul
cancer
promot
tumor
cell
prolifer
surviv
also
reduc
respons
may
blunt
magnitud
local
antitumor
immun
respons
thu
silenc
could
antitumor
effect
sever
level
recogn
cpg
motif
dna
cytosin
methyl
mammalian
dna
context
cpg
dinucleotid
bacteri
genom
modifi
way
express
subset
immun
cell
includ
b
cell
plasmacytoid
dc
mice
human
also
express
monocyt
myeloid
dc
primarili
locat
endosom
compart
cell
express
take
cpgmotif
dna
intern
even
though
present
cell
surfac
ie
directli
involv
intern
kortylewski
demonstr
cpg
oligonucleotid
plu
link
sirna
cargo
taken
cell
fraction
materi
escap
endosom
sequestr
cytoplasm
effect
suppress
express
cell
take
dna
whether
cpg
motif
present
combin
cpgmotif
nucleic
acid
seem
improv
deliveri
sirna
cargo
cytoplasm
direct
peritumor
inject
conjug
reduc
size
sc
tumor
implant
furthermor
direct
iv
administr
conjug
significantli
reduc
size
number
pulmonari
implant
develop
follow
iv
inject
melanoma
cell
syngen
mice
although
commonli
use
iv
administr
absenc
deliveri
aid
tammali
colleagu
inject
nake
chemicallystabil
sistabl
sirna
mice
demonstr
role
aldos
reductas
colon
cancer
metastasi
egfpexpress
human
colon
cancer
cell
inject
intrasplen
nude
mice
gener
model
colon
cancer
number
implant
reduc
iv
administr
sirna
three
dose
deliv
iv
mice
everi
day
knockdown
measur
rtqpcr
mice
dose
sirna
demonstr
knockdown
mrna
liver
treat
mice
compar
neg
control
overal
inhibit
led
decreas
cell
adhes
epitheli
cell
invas
migrat
clinic
trialsconjug
nake
sirna
iv
current
clinic
trial
ongo
use
direct
sirnaligand
conjug
human
howev
one
sirna
drug
studi
employ
nake
iv
administr
without
target
ligand
vehicl
facilit
deliveri
sirna
drug
clinic
trial
sponsor
quark
pharmaceut
first
phase
doseescal
trial
evalu
inhibitor
mean
prevent
acut
kidney
renal
injuri
patient
undergon
major
cardiovascular
surgeri
http
current
evalu
phase
iii
doseescal
studi
determin
efficaci
prophylact
treatment
delay
graft
function
kidney
transplant
patient
http
blunt
sirna
heavili
modifi
residu
administ
iv
nake
form
without
deliveri
aid
take
advantag
observ
high
dose
nucleic
acid
serum
achiev
entri
cell
proxim
convolut
tubul
kidney
highli
concentr
urinari
excret
inorgan
particl
gold
nanoparticl
amen
surfac
function
permit
load
variou
biomolecul
find
grow
number
applic
vivo
use
includ
deliveri
nucleic
acid
aso
sirna
method
develop
trigger
releas
sirna
attach
gold
particl
follow
exposur
nir
light
take
advantag
surfaceplasmon
reson
properti
materi
nir
light
nm
wavelength
rang
excel
tissu
penetr
easili
adapt
vivo
use
lu
colleagu
employ
hollow
gold
nanospher
haun
nir
irradi
deliv
sirna
nude
mice
bear
hela
cell
implant
hind
limb
use
thiocyt
acidtermin
peg
linker
folic
acid
coupl
gold
particl
target
ligand
increas
particl
uptak
tumor
cell
unmodifi
sirna
target
rela
nuclear
subunit
attach
particl
via
sulfhydryl
linker
connect
sirna
passeng
strand
gold
surfac
result
final
fpeghaunssirna
particl
particl
uptak
biodistribut
studi
use
pet
imag
follow
iv
inject
fpeghaunssirna
label
dota
cu
folateconjug
nontarget
particl
show
signific
uptak
liver
spleen
howev
folat
target
confer
select
shown
fivefold
increas
tumor
implant
uptak
mice
administ
singl
mgkg
iv
dose
fpeghaunssirna
one
hind
limb
receiv
nir
irradi
hour
postinject
mwcm
tumor
implant
remov
hour
later
western
blot
immunohistochem
evalu
indic
subunit
suppress
tumor
treat
fpeghaunsantirelasirna
plu
nir
without
nir
treatment
use
control
sirna
particl
combin
therapi
use
singl
dose
fpeghaunsantirelasirna
nanoparticl
nir
treatment
two
dose
irinotecan
topoisomeras
inhibitor
led
complet
inhibit
tumor
implant
growth
day
ip
administr
ip
administr
sirna
repres
anoth
rout
achiev
local
even
system
effect
vivo
may
fewer
toxic
issu
direct
iv
inject
dose
rout
allow
direct
transport
inject
nanoparticl
via
circulatori
system
way
iv
dose
rather
system
distribut
ip
administr
depend
upon
indirect
distribut
initi
movement
organ
well
migrat
via
lymphat
system
ip
administr
advantag
compar
iv
deliveri
serum
protein
contribut
polyplex
aggreg
preval
sinc
ipdos
particl
need
extravas
venou
fenestra
order
reach
target
tissu
interest
less
requir
particl
small
diamet
need
iv
deliveri
sever
system
sirna
experi
util
ip
deliveri
rout
due
advantag
particular
follow
studi
address
sirna
deliveri
ovarian
cancer
cancer
model
ip
deliveri
commonli
use
treat
ovarian
cancer
murin
model
studi
describ
whole
anim
imag
section
demonstr
tumor
regress
lipidoidformul
nanoparticl
carri
sirna
ip
dose
sirna
target
deliv
twice
weekli
per
inject
treatment
reduc
incid
metastas
gave
detect
immun
respons
multipl
dose
ovarian
cancer
treat
sirna
fak
formul
reconstitut
hdl
nanoparticl
discuss
previous
sirna
mgkg
dose
combin
chemotherapeut
agent
led
signific
decreas
tumor
weight
number
tumor
nodul
present
follow
ip
well
iv
deliveri
addit
ip
deliveri
show
potenti
ovarian
cancer
treatment
use
neutral
dopc
liposom
contain
sirna
target
liposomesirna
ipdos
mous
model
advanc
ovarian
cancer
twice
weekli
week
compar
mice
receiv
paclitaxel
control
sirnadopc
liposom
reduct
tumor
growth
observ
mice
treat
pacitaxel
sirnadopc
liposom
halder
colleagu
target
fak
protein
known
play
role
ovarian
cancer
metastasi
similar
neutral
lipidsirna
formul
dose
regimen
use
studi
result
similar
observ
hdl
nanoparticl
experi
decreas
tumor
growth
mice
dose
sirna
compar
neg
control
reduct
even
signific
rnai
therapi
combin
known
chemotherapeut
agent
given
propens
metastasi
spread
throughout
periton
caviti
advanc
ovarian
cancer
ip
method
treatment
includ
ip
chemotherapi
common
medic
practic
today
anoth
studi
use
ip
deliveri
treatment
ovarian
cancer
mice
sirna
formul
lipidoid
identifi
compound
librari
screen
highli
effect
transfect
ovarian
cancer
cell
vitro
sirna
three
dose
mgkg
deliv
ip
two
mous
model
ovarian
cancer
use
cell
wildtyp
cell
rna
isol
tumor
show
knockdown
surviv
extend
tumor
model
wildtyp
model
confirm
specif
mechan
lethal
requir
defici
induc
apoptosi
similarli
peiformul
unmodifi
sirna
target
dose
ip
dose
cours
week
micebear
human
xenograft
tumor
tumor
regress
observ
suggest
mitot
spindl
checkpoint
may
therapeut
target
ip
deliveri
ovarian
cancer
asid
ovarian
cancer
xenograft
cancer
model
effect
target
ip
deliveri
sirna
interestingli
sirna
tissu
factor
abl
reduc
metastat
colon
lung
tissu
melanoma
cell
inject
iv
metastat
challeng
time
immedi
follow
ip
deliveri
sirna
unmodifi
sirna
complex
mice
dose
three
time
initi
dose
deliv
hour
tumor
challeng
subsequ
dose
given
day
posttumor
challeng
number
lung
tumor
present
day
cell
ivinject
decreas
control
group
mice
treat
sirna
tesnier
colleagu
report
use
sirna
target
tbet
transcript
factor
requir
develop
helper
cell
respect
immunomodul
relat
antitumor
vaccin
nake
unmodifi
sirna
dose
day
deliv
ip
vaccin
tumorbear
mous
model
lead
immunostimul
reduc
tumor
growth
howev
simultan
treatment
sirna
result
uninhibit
tumor
growth
demonstr
antagonist
effect
subpopul
helper
cell
anticanc
immun
respons
absorpt
system
distribut
small
molecul
drug
follow
ip
inject
well
accept
small
nanoparticl
rapidli
clear
periton
caviti
absorb
lymphat
circul
clear
spleen
may
limit
effici
system
deliveri
although
work
gao
cowork
chitosansirna
nanoparticl
indic
presenc
sirna
blood
minut
follow
ip
dose
one
way
circumv
potenti
problem
target
mobil
popul
cell
like
macrophag
resid
periton
caviti
reservoir
cell
transfect
sirna
free
migrat
system
effect
bring
sirna
cargo
approach
like
use
target
macrophag
mean
modul
diseas
inflammatori
compon
use
sirna
target
tnf
product
macrophag
ip
deliveri
exploit
sever
recent
studi
studi
lundberg
colleagu
employ
antitnf
dsirna
studi
role
tnf
pathophysiolog
herp
simplex
virusinduc
enceph
transittko
use
formul
dsirna
ip
deliveri
dose
six
inject
day
interestingli
ip
inject
dsirna
cation
lipid
complex
abl
influenc
diseas
process
cn
presum
result
due
direct
cn
deliveri
dsirna
rather
transfect
periton
macrophag
antitnf
dsirna
later
migrat
site
inflamm
cn
studi
highlight
complex
role
tnf
play
surviv
herp
enceph
suggest
exist
unknown
third
tnf
receptor
mice
experi
doubleknockout
two
known
tnf
receptor
howard
kjem
colleagu
develop
chitosan
nanoparticl
employ
vivo
use
intratrach
ip
rout
administr
group
employ
antitnf
dsirna
previous
use
lundberg
moder
sever
murin
collageninduc
arthriti
antitnf
dsirnachitosan
complex
administ
ip
inject
dose
mgkg
everi
day
total
dose
start
onset
overt
arthriti
week
collagen
immun
unmodifi
antitnf
dsirna
show
improv
arthrit
score
howev
duplex
perform
better
subsequ
histolog
evalu
joint
show
evid
eros
destruct
articular
surfac
cohort
anim
group
later
employ
antitnfchitosan
formul
prevent
develop
radiationinduc
fibrosi
follow
highdos
gamma
irradi
hind
limb
antitnfchitosan
administ
ip
mice
given
gy
irradi
singl
hind
limb
develop
contractur
radiationinduc
fibrosi
monitor
compar
nonirradi
contralater
control
limb
dsirnachitosan
treatment
given
ip
inject
day
prior
irradi
twice
weekli
variabl
period
time
thereaft
control
mice
treat
antitnf
dsirna
day
develop
radiationinduc
fibrosi
mice
treat
day
day
day
howev
show
evid
fibrosi
offer
hope
potenti
treatment
prevent
morbid
associ
radiat
therapi
current
clinic
trial
ongo
use
synthet
sirna
ip
deliveri
human
clinic
applic
tissuespecif
dose
rout
attract
due
increas
target
tissu
bioavail
select
reduc
dose
sirna
requir
compar
system
rout
administr
especi
iv
deliveri
direct
inject
sirna
intend
site
action
reduc
consider
might
otherwis
need
tissuespecif
target
addit
need
extens
nucleas
stabilizationwheth
mean
modifi
nucleotid
formul
carrier
moleculei
high
prioriti
system
deliveri
sirna
expos
serum
section
discuss
sever
type
formul
sirna
modif
etc
success
use
mediat
gene
knockdown
relief
diseaseassoci
phenotyp
via
direct
local
administr
direct
cn
administr
larg
molecul
small
molecul
drug
routin
administ
cn
direct
inject
bbb
normal
prevent
entri
arteri
circul
unlik
serum
cerebrospin
fluid
rel
nucleas
poor
environ
reduc
extent
chemic
modif
need
protect
sirna
degrad
deliveri
cn
deliveri
option
includ
intrathec
intraventricular
epidur
direct
intratissu
intratumor
inject
compound
administ
singl
bolu
slow
continu
longterm
infus
use
mini
pump
report
vari
need
deliveri
aid
cn
research
report
seemingli
success
result
use
highdos
nake
infus
other
report
signific
benefit
employ
lipid
polym
peptid
deliveri
vehicl
use
deliveri
aid
certainli
reduc
amount
sirna
need
administr
altier
colleagu
use
bolu
intrathec
deliveri
suppress
specif
calcium
channel
defin
role
nocicept
rat
dose
three
time
day
unmodifi
sirna
water
mgkg
use
deliveri
aid
target
exon
ntype
calcium
channel
result
pain
test
rat
indic
voltageg
calcium
channel
contain
transmembran
protein
play
role
thermal
nocicept
develop
thermal
mechan
hyperalgesia
follow
formalin
inject
sciatic
nerv
constrict
effect
painrel
stimuli
decreas
upon
treatment
sirna
target
exon
ntype
calcium
channel
help
identifi
role
transmembran
protein
type
respons
taishi
colleagu
also
employ
direct
bolu
inject
unmodifi
sirna
salin
brain
tissu
case
studi
tnf
play
role
sleep
regul
rat
administ
nmole
antitnf
sirna
twice
week
mgkg
via
direct
microinject
somatosensori
cortex
one
side
brain
receiv
antitnf
sirna
contralater
side
receiv
control
sirna
rtqpcr
indic
reduct
tnf
mrna
antitnf
treat
tissu
compar
control
tissu
electrophysiolog
studi
show
reduct
tnf
level
correl
reduc
electroencephalogram
delta
wave
power
suggest
role
cytokin
sleep
regul
chronic
intraventricular
dose
use
deliv
sirna
target
amyloid
precursor
protein
gene
app
adult
mice
investig
effect
gene
product
alzheimersrel
function
altern
use
app
knockout
mice
total
devoid
app
throughout
develop
miniosmot
pump
implant
sc
mice
deliv
unmodifi
antiapp
sirna
direct
intraventricular
infus
daili
mgkg
direct
infus
brain
week
antiapp
sirna
concentr
isoton
buffer
deliveri
aid
via
insitu
hybrid
potent
sirna
sequenc
shown
reduc
app
mrna
region
hippocampu
knockdown
correl
impair
hippocampusdepend
spatial
work
memori
via
locomot
maze
test
also
use
nake
unassist
deliveri
buffer
salin
mccormack
colleagu
employ
chronic
infus
chemicallystabil
sirna
nonhuman
primat
squirrel
monkey
suppress
level
overexpress
protein
correl
sever
neurodegen
disord
includ
parkinson
diseas
direct
infus
substantia
nigra
achiev
use
implant
alzet
miniosmot
pump
flow
rate
cours
week
sirna
pyrimidin
termin
ps
linkag
strand
snca
mrna
level
evalu
qpcr
shown
reduc
rel
treatment
nontarget
control
sirna
likewis
immunohistochemistri
tissu
section
show
protein
decreas
substantia
nigra
howev
phenotyp
chang
observ
likewis
wang
colleagu
employ
chronic
infus
chemicallymodifi
sirna
cn
mice
alzet
osmot
infus
pump
mous
model
amyotroph
later
sclerosi
al
case
sirna
select
modifi
ps
linkag
residu
near
end
strand
follow
infus
sirna
cours
one
week
northern
blot
show
dose
sirna
decreas
mrna
level
spinal
cord
nearundetect
level
compar
neg
control
transgen
mous
model
al
infus
sirna
significantli
slow
diseas
progress
sirna
shown
stabl
cours
day
studi
sirna
administ
cn
target
neuron
recent
studi
querb
colleagu
demonstr
chronic
infus
chemicallymodifi
sirna
phosphatebuff
salin
pb
also
target
oligodendrocyt
oligodendrocyt
specif
gene
nucleotid
cnp
target
use
sirna
pyrimidin
termin
ps
linkag
strand
similar
design
employ
mccormick
sirna
administ
use
implant
alzet
osmot
pump
rat
dose
rate
mgkgday
day
rhesu
monkey
dose
mgkgday
day
reduct
cnp
mrna
shown
use
rtqpcr
rnai
mechan
action
proven
use
two
recent
studi
demonstr
use
ligandcoupl
sirna
within
cn
difiglia
colleagu
employ
cholesterolconjug
sirna
termin
ps
linkag
use
direct
intrastriat
inject
target
mutant
htt
evalu
role
huntington
diseas
administr
singl
nmole
dose
cholesterolsirna
led
decreas
mutant
htt
protein
improv
viabil
striatal
neuron
smaller
inclus
size
reduc
sign
motor
disturb
gait
test
uno
colleagu
conjug
dsirna
linkag
vitamin
e
deliveri
ligand
sirna
target
target
interest
treatment
alzheim
diseas
modifi
sirna
deliv
either
pb
mixtur
purifi
hdl
use
continu
intracerebroventricular
infus
osmot
minipump
day
uptak
vitamin
e
cell
normal
involv
complex
ldl
entri
liver
hdl
entri
tissu
author
compar
perform
unconjug
sirna
vitamin
econjug
sirna
vitamin
econjug
sirna
plu
hdl
vitamin
econjug
sirna
mix
purifi
hdl
significantli
outperform
formul
show
maxim
knockdown
hippocampu
pariet
cortex
respect
measur
rtqpcr
without
addit
hdl
unconjug
sirna
perform
nearli
well
vitamin
econjug
sirna
neither
significantli
differ
neg
control
highlight
benefit
ad
purifi
hdl
use
vitamin
e
conjug
number
group
employ
cation
lipidassist
deliveri
cn
exampl
lacroixfralish
colleagu
establish
role
subunit
na
k
atpas
pump
sourc
interstrain
variabl
earli
phase
pain
respons
formalin
chemic
burn
mous
strain
aj
exhibit
less
pronounc
pain
respons
formalin
inject
foot
pad
mous
strain
genet
map
quantit
trait
locu
analysi
tent
identifi
gene
implic
differ
pain
respons
mous
strain
gene
heretofor
consid
import
nocicept
test
hypothesi
dsirna
administ
lumbar
spinal
cord
mice
strain
inject
dose
mgkg
cation
lipid
ifect
hour
interv
total
inject
mice
studi
formalin
pain
respons
mice
receiv
vehicl
alon
control
dsirna
inject
show
expect
behavior
differ
strain
howev
mice
given
dsirna
show
ident
behavior
strain
earli
phase
pain
respons
pattern
ident
two
differ
dsirna
confirm
role
gene
product
nocicept
also
use
lipidassist
deliveri
sirna
cn
doresavard
colleagu
studi
role
gpcr
neurotensin
receptor
rat
thermal
nocicept
stimul
synthet
agonist
result
analgesia
suppress
receptor
rnai
block
analges
effect
expect
compound
dsirna
administ
two
inject
vertebra
hour
apart
dose
mgkg
cation
lipid
ifect
agonist
given
day
rat
test
thermal
nocicept
analges
respons
total
block
day
follow
last
dsirna
inject
gradual
return
baselin
thereaft
mrna
protein
level
demonstr
significantli
reduc
dorsal
root
ganglia
day
consist
observ
phenotyp
respons
two
differ
dsirna
demonstr
result
effect
suppress
express
alter
nocicept
respons
ifect
lipid
greatli
improv
deliveri
dsirna
rat
spinal
cord
dorsal
root
ganglia
use
lipidsirna
cocktail
limit
acut
pain
studi
vehicl
alon
alter
anim
behavior
attempt
perform
similar
studi
use
tonic
chronic
pain
model
system
nicola
beaudet
univers
sherbrook
person
commun
problem
solv
shift
use
peptid
deliveri
tool
transductin
see
discuss
dong
colleagu
also
employ
ifect
cation
lipid
deliv
sirna
rat
lumbar
spinal
cord
use
epidur
cathet
pain
model
employ
sciatic
nerv
ligat
unmodifi
sirna
target
na
v
tetrodotoxin
resist
sodium
channel
administ
dose
mgkg
four
time
day
mechan
allodynia
significantli
revers
anim
receiv
sirna
control
sirna
correl
decreas
mrna
confirm
rtqpcr
one
addit
studi
lipidformul
sirna
deliv
cn
tissu
dotapcholesterol
carrier
use
deliv
antijun
sirna
striatum
mice
show
knockdown
report
gene
express
result
observ
hour
follow
singl
dose
sirna
cpp
peptid
transduct
domain
ptd
employ
deliv
varieti
cargo
cell
success
direct
conjug
nucleic
acid
problemat
expect
possibl
cation
peptid
electrostat
complex
anion
nucleic
acid
result
charg
neutral
blunt
effect
ptd
mediat
transduct
eguchi
colleagu
recent
describ
develop
novel
chimer
peptid
deliveri
tool
fuse
tat
ptd
dsrnabind
domain
drbd
mammalian
rnabind
protein
result
peptid
call
ptddrbd
shown
direct
function
deliveri
sirna
wide
varieti
cell
type
vitro
markedli
reduc
ote
compar
tradit
cation
lipid
mediat
transfect
ptddrbd
construct
commerci
avail
transductin
michiu
colleagu
establish
mous
glioblastoma
model
stereotact
implant
human
cell
right
corpu
striatum
nude
mice
mice
dose
direct
intratumor
cn
inject
variou
unmodifi
sirna
complex
ptddrbd
dose
pmole
mgkg
day
postimplant
sirna
target
egfr
test
treatment
singl
sirna
sequenc
result
tumor
regress
howev
treatment
combin
antiegfr
sirna
plu
sirna
sirna
result
apoptosi
tumor
cell
markedli
improv
surviv
carbon
nanotub
new
materi
potenti
use
nucleic
acid
deliveri
carbon
nanotub
derivat
sirna
target
employ
cn
deliveri
aljam
colleagu
deliv
cortex
rat
stereotact
inject
either
prior
follow
induct
stroke
administr
potent
vasoconstrictor
sirnacarbon
nanotub
deliv
hour
prior
administr
anti
sirna
treatment
group
show
signific
decreas
apoptot
cell
measur
tunnel
assay
carbon
nanotub
dose
hour
follow
stroke
induct
show
decreas
apoptosi
differ
compar
neg
control
signific
current
clinic
trial
ongo
use
synthet
sirna
cn
deliveri
human
topic
administr
topic
administr
section
includ
transderm
mucos
use
sirna
anim
transderm
deliveri
sirna
use
knockdown
varieti
diseaserel
target
skin
excel
review
use
lipidbas
agent
topic
deliveri
nucleic
acid
recent
publish
geusen
notabl
work
field
come
kaspar
lab
work
treatment
pachyonychia
congenita
pc
rare
skin
disord
caus
mutat
one
mani
keratin
gene
character
thicken
nail
pain
disabl
palmoplantar
hyperkeratosi
thu
far
differ
mutat
associ
pc
identifi
common
affect
aminoacid
posit
keratin
gene
detail
see
recent
review
field
leachman
earli
work
lab
indic
unmodifi
sirna
may
suitabl
nake
deliveri
skin
success
uptak
sirna
target
cell
shown
use
confoc
microscopi
empir
screen
set
sirna
tile
site
mutat
identifi
potent
allelespecif
sirna
sequenc
select
suppress
mutant
form
gene
lead
candid
work
taken
phase
clinic
trial
see
util
direct
inject
unmodifi
nake
sirna
salin
plantar
hyperkeratot
lesion
result
studi
perform
singl
patient
report
last
year
encourag
transient
improv
observ
site
inject
sever
pain
associ
direct
inject
prove
limit
studi
result
group
sinc
shift
studi
use
transderm
deliveri
cream
genecream
transderm
highli
modifi
selfdeliv
sirna
could
potenti
appli
topic
formul
therapeut
applic
peptid
also
use
facilit
transderm
deliveri
sirna
mice
uchida
colleagu
studi
use
two
differ
peptid
deliveri
aid
fcigrlcg
recent
identifi
modul
intracellular
tight
junction
direct
paracellular
transport
tat
grkkrrnrrrcg
wellknown
cpp
two
peptid
complex
fluoresceinlabel
sirna
small
volum
appli
back
shave
mice
combin
peptid
complex
sirna
led
deepest
wide
dispers
dye
signal
observ
confoc
microscopi
result
suggest
complex
mediat
transcellular
intracellular
deliveri
optim
transderm
deliveri
sirna
takanashi
colleagu
describ
use
lipidalcoholbas
formul
call
genecream
obtain
transderm
group
employ
unmodifi
sirna
target
osteopontin
extracellular
matrix
cytokin
known
involv
pathogenesi
autoimmun
inflammatori
arthriti
reduc
sever
collageninduc
arthriti
mice
sirna
administ
topic
mgday
genecream
paw
mice
mark
reduct
joint
swell
observ
mice
receiv
sirnagenecream
formul
receiv
scrambl
sirna
vehicleonli
control
joint
histolog
show
signific
reduct
inflamm
reminisc
imag
seen
collageninduc
arthriti
mice
use
ip
inject
antitnf
dsirna
chitosan
vehicl
previous
discuss
cholesterolconjug
sirna
linkag
directli
administ
intravagin
epithelium
mice
two
sirna
employ
sirna
sequenc
target
gene
herp
simplex
viru
combin
sirna
sequenc
target
host
factor
use
sirna
alon
gave
hour
protect
time
applic
use
sirna
show
delay
longer
last
activ
topic
administr
sirna
togeth
provid
protect
viral
challeng
cours
week
previou
work
group
show
slight
signific
inflamm
unmodifi
sirna
appli
vagin
mucosa
cation
lipid
formul
present
studi
combin
use
cholesterol
ps
modif
result
stabl
molecul
could
use
nake
deliveri
elimin
toxic
associ
deliveri
vehicl
clinic
trialstransderm
deliveri
discuss
test
phase
clinic
trial
treatment
pc
singl
patient
known
mutat
gene
trial
repres
first
time
mutationspecif
sirna
sequenc
evalu
human
studi
complet
late
sponsor
pc
project
associ
transderm
inc
http
patient
assess
physiciandetermin
clinic
efficaci
metric
reveal
regress
callu
sirnatr
lesion
vehicletr
foot
pain
associ
direct
inject
callu
limit
rout
administr
investig
side
effect
observ
could
directli
ascrib
sirna
drug
clinic
studi
perform
china
cpp
sirna
formul
use
peptid
acssspskhcggrrrrrrrr
use
topic
administr
sirna
target
microphthalmiaassoci
transcript
factor
mitf
antimitf
sirna
formul
cream
treat
hyperpig
hypermelanin
facial
lesion
disord
known
melasma
mitf
microphthalmiaassoci
transcript
factor
major
regul
melanocyt
develop
possibl
target
treat
condit
involv
hyperpigment
total
patient
enrol
moder
sever
facial
lesion
studi
group
receiv
antimitf
sirna
cream
control
group
receiv
cream
clinic
evalu
end
week
studi
show
signific
lighten
skin
expect
mitf
inhibit
patient
receiv
antimitfsirna
cream
clinic
trial
http
sponsor
duke
univers
recruit
phase
involv
ex
vivo
sirna
transfect
dc
use
vaccin
patient
confirm
metastat
melanoma
preclin
result
demonstr
sirna
target
immunoproteosom
dc
subsequ
transfect
rna
encod
melanoma
antigen
led
improv
induct
cytotox
lymphocyt
target
melanoma
cell
phase
studi
dc
optim
antigen
present
administ
via
intraderm
inject
toxic
clinic
respons
follow
vaccin
current
evalu
intratumor
inject
commonli
use
strategi
queri
role
specif
oncogen
sc
tumor
model
rodent
rout
dose
necessarili
requir
much
protect
sirna
nucleas
degrad
chemic
modif
complex
deliveri
vehicl
iv
administr
remov
issu
associ
system
deliveri
advantag
local
deliveri
usual
requir
significantli
lower
total
dose
sirna
subcutan
implant
melanoma
cell
syngen
mice
use
test
role
tumor
growth
singl
intratumor
inject
nake
unmodifi
sirna
pb
target
stressrespons
membran
protein
result
tumor
regress
almost
day
result
seen
treatment
use
antibodi
ps
antisens
dna
oligonucleotid
direct
valid
use
target
treatment
melanoma
also
use
nake
deliveri
suo
colleagu
treat
gastric
cancer
vivo
unmodifi
sirna
target
anion
exchang
establish
sc
tumor
cell
directli
inject
dose
sirna
everi
day
day
western
blot
analysi
show
almost
complet
knockdown
protein
express
tumor
volum
less
neg
control
mice
formul
sirna
cation
lipid
common
approach
use
improv
deliveri
follow
direct
local
inject
sever
report
use
method
discuss
dharmapuri
colleagu
use
sirna
target
cell
cycl
regul
formul
lipid
nanoparticl
provid
sirnamerck
suppress
growth
sc
xenogen
tumor
implant
nude
mice
sirna
directli
inject
tumor
mass
dose
volum
use
variabl
dose
regimen
averag
rate
tumor
growth
reduc
use
approach
malign
glioblastoma
cancer
high
mortal
effect
treatment
liu
colleagu
postul
disrupt
iron
homeostasi
glioma
cell
use
sirna
target
heavi
chain
ferritin
would
impair
energi
metabol
reduc
cell
growth
rate
make
cell
suscept
tradit
chemotherapeut
agent
sirna
formul
cholesterol
dope
liposom
deliv
intratumor
inject
weekli
sc
implant
glioma
cell
nude
mice
bcnu
bischloroethylnitrosourea
standard
chemotherapeut
agent
treatment
glioblastoma
administ
hour
sirna
treatment
tumor
volum
sirnatr
mice
half
observ
control
anim
indic
treatment
sensit
tumor
chemotherapi
high
percentag
human
cervic
cancer
link
infect
human
papilloma
viru
hpv
particularli
strain
viral
gene
product
direct
degrad
retinoblastoma
protein
prb
endogen
tumorsuppressor
target
ubiquitin
reduc
prb
level
lead
derepress
certain
transcript
factor
turn
lead
cell
divis
time
viral
gene
product
block
compensatori
upregul
normal
occur
regulatori
respons
uncontrol
cell
divis
thu
combin
action
viral
gene
product
need
produc
malign
phenotyp
gene
therefor
ideal
target
nucleic
acidbas
therapi
treatment
hpvderiv
tumor
direct
intratumor
inject
nake
highli
modifi
sistabl
sirna
target
hpv
gene
studi
jonson
colleagu
sc
tumor
implant
ovarian
cancer
cell
mice
caski
cell
hpv
treat
everi
day
pmoledos
salin
mgkgdose
day
size
sirnatr
tumor
significantli
smaller
salinetr
control
sirnatr
implant
yamato
colleagu
took
similar
approach
studi
use
care
optim
unmodifi
sirna
directli
inject
sc
tumor
mice
deriv
siha
cell
cervic
cancer
line
case
sirna
complex
atelocollagen
dose
pmole
per
inject
everi
day
day
dramat
regress
tumor
observ
sirnatr
anim
number
research
employ
nucleic
acidbas
antihpv
treatment
treatment
cervic
cancer
includ
express
shrna
deliv
lentivir
vector
sirna
deliv
iv
use
lipidbas
nanoparticl
seth
colleagu
describ
use
sirna
formul
dila
lipid
nanoparticl
direct
intravesicular
infus
local
treatment
bladder
cancer
implant
mice
sirna
employ
unamodifi
duplex
target
survivin
polo
like
kinas
gene
human
bladder
cancer
cell
engin
express
luciferas
report
grown
intravesicular
implant
nude
mice
sirnalipid
nanoparticl
administ
intravesicular
infus
dose
mgkg
day
tumor
implant
tumor
growth
assess
vivo
bli
show
reduct
tumor
growth
rate
treat
anim
compar
control
correl
reduct
mrna
rtqpcr
assay
rnai
mechan
action
confirm
analysi
number
research
report
success
use
pei
sirna
deliveri
tool
direct
local
inject
rout
administr
bypass
toxic
concern
sometim
limit
pei
use
follow
system
iv
inject
sc
murin
glioma
model
unmodifi
sirna
formul
jetpei
dose
everi
third
day
day
use
direct
intratumor
inject
mgkgdose
sirna
treatment
significantli
reduc
size
establish
tumor
almost
total
prevent
growth
smaller
tumor
similarli
chen
colleagu
use
unmodifi
sirna
target
formul
pei
direct
inject
sc
tumor
implant
mice
dominantneg
splice
variant
kruppellik
factor
gene
thought
play
role
develop
gastric
carcinoma
prolifer
two
differ
gastric
cancer
cell
line
cell
reduc
follow
treatment
even
singl
dose
mgkg
sirna
compar
control
sirna
electropor
commonli
use
vitro
promot
cellular
uptak
dna
rna
particularli
cell
line
difficult
transfect
cation
lipid
also
appli
vivo
local
deliveri
nucleic
acid
golzio
colleagu
report
use
unmodifi
antiegfp
sirna
suppress
fluoresc
melanoma
cell
grow
syngen
mice
sc
implant
cell
stabli
express
egfp
offer
conveni
report
system
singl
dose
sirna
pb
inject
tumor
follow
electropor
site
inject
use
puls
ms
durat
hz
frequenc
egfp
fluoresc
suppress
day
posttreat
wholebodi
imag
show
signific
decreas
fluoresc
siegfptreat
mice
neg
control
anim
nakai
colleagu
also
employ
electropor
deliv
nake
unmodifi
sirna
mice
gene
target
microphthalmiaassoci
transcript
factor
mitf
regul
melanocyt
differenti
involv
melanin
synthesi
case
suppress
mitf
test
mean
reduc
growth
melanoma
cell
syngen
mice
consecut
x
dose
sirna
administ
daili
first
day
studi
follow
direct
inject
sirna
pb
tumor
mass
local
electropor
perform
use
puls
ms
durat
hz
frequenc
mice
receiv
antimitf
sirna
via
electropor
show
tumor
growth
first
day
antigfp
sirna
pb
alon
nontreat
control
mice
show
tumor
growth
day
day
tumor
volum
doubl
neg
control
cohort
rel
antimitf
sirnatr
anim
peptid
carrier
sirna
often
perceiv
lower
toxic
biodegrad
deliveri
system
result
aminoacid
monom
recent
disulfidelink
polyarginin
demonstr
vivo
util
deliv
sirna
use
direct
inject
sc
tumor
unmodifi
sirna
target
vegf
condens
presenc
cysteineflank
peptid
cysarg
cy
discret
particl
mean
size
nm
vitro
studi
show
polyplex
readili
reduc
cytoplasm
cell
contain
rel
high
cytoplasm
concentr
glutathion
vivo
growth
rate
sc
tumor
reduc
two
intratumor
dose
deliv
weekli
clinic
trialsintratumor
deliveri
silense
launch
phase
trial
patient
oper
adenocarcinoma
pancrea
safeti
toler
studi
loder
http
sirna
sequenc
target
mutat
deliv
biodegrad
polymer
matrix
loder
formul
dose
directli
adenocarcinoma
via
biopsi
needl
intranasalinh
administr
inhal
spray
common
method
deliv
small
molecul
drug
respiratori
system
direct
nasal
intratrach
administr
one
earli
rout
employ
vivo
sirna
deliveri
often
target
tissu
epitheli
line
lung
howev
traffick
sirna
nanoparticl
mucou
layer
line
epithelium
signific
barrier
method
deliveri
nevertheless
favor
result
report
use
approach
yueksekdag
colleagu
employ
intranas
administr
nake
unmodifi
sirna
mice
group
studi
suppress
amiloridesensit
epitheli
na
channel
target
interest
treatment
cystic
fibrosi
singl
perfus
sirna
water
lead
detect
reduct
mrna
howev
dose
sirna
cours
day
result
decreas
express
assay
rtqpcr
use
sirna
treat
respiratori
virus
area
particular
focu
small
molecul
drug
exist
effect
treat
pathogen
sirnabas
treatment
influenza
viru
sar
corona
viru
infect
discuss
previou
review
improv
method
treat
respiratori
infect
use
modifi
sirna
recent
review
barik
mous
model
equin
herp
viru
infect
sirna
target
key
viral
envelop
glycoprotein
helicas
deliv
hour
prior
infect
hour
follow
infect
intranas
infus
use
dose
rang
pmole
mgkg
less
either
pb
cation
lipid
lipofectamin
larg
reduct
plaqueform
unit
per
mg
lung
tissu
seen
combin
therapi
one
sirna
sequenc
effect
use
singl
agent
interestingli
sirna
deliv
pb
gener
effect
deliv
cation
lipid
formul
studi
treatment
viral
infect
import
consid
control
effect
immun
stimul
dsrna
side
effect
may
contribut
observ
antivir
effect
clinic
trialsintranasalinh
deliveri
unmodifi
sirna
alnylam
pharmaceut
current
studi
treatment
respiratori
syncyti
viru
rsv
via
intranasalinh
administr
administ
without
deliveri
aid
disrupt
integr
normal
airtissu
interfac
mucu
barrier
viral
infect
may
facilit
deliveri
lung
tissu
normal
well
defend
entri
foreign
materi
phase
doseescal
toler
studi
complet
total
healthi
adult
treat
placebo
normal
salin
advers
effect
observ
dose
mg
administ
five
time
daili
side
effect
seen
moder
occur
similar
frequenc
treatment
group
placebo
group
phase
studi
evalu
healthi
human
volunt
inocul
rsv
deliv
intranas
mg
day
prior
day
follow
rsv
infect
placebotr
group
show
rsv
infect
wherea
recipi
culturedefin
rsv
infect
evalu
natur
infect
patient
recent
complet
lungtranspl
patient
infect
rsv
three
daili
treatment
aerosol
mgkg
result
improv
rsv
symptom
reflect
cumul
daili
total
symptom
score
addit
treatment
lead
reduct
incid
bronchiol
obliteran
bo
fibrosisinflamm
bronchiol
follow
rsv
infect
phase
iib
clinic
trial
open
februari
evalu
efficaci
safeti
aerosol
well
standard
care
lungtranspl
patient
infect
rsv
http
wwwclinicaltri
primari
outcom
measur
studi
current
recruit
patient
occurr
new
progress
bo
zabecor
pharmaceut
report
complet
phase
clinic
trial
excellair
sirna
drug
target
spleen
tyrosin
kinas
syk
treatment
asthma
http
wwwzabecor
patient
receiv
excellair
inhal
daili
day
seriou
side
effect
report
indic
improv
breath
addit
zabecor
announc
launch
phase
ii
clinic
trial
detail
trial
pennsylvaniabas
compani
publish
optic
administr
due
uniqu
abil
deliv
drug
use
direct
local
intravitr
inject
ocular
diseas
among
first
indic
investig
sirnabas
therapeut
ocular
deliveri
nucleic
acidbas
drug
recent
review
fattal
campochiaro
earliest
studi
report
literatur
employ
direct
intravitr
inject
nake
sirna
work
murata
colleagu
use
lipidfacilit
deliveri
subconjunctiv
inject
larg
set
sirna
target
particular
gene
made
use
pcr
vitro
transcript
dicer
pool
collect
antivegf
dicedsirna
formul
lipofectamin
administ
subconjunctiv
inject
rat
sutureinduc
corneal
angiogenesi
model
system
treatment
pool
antivegf
sirna
significantli
reduc
angiogenesi
therapi
reduc
neovascular
interest
treatment
wet
agerel
macular
degener
amd
diabet
retinopathi
anoth
studi
use
lipidassist
deliveri
fluoresc
label
sirna
formul
transittko
administ
direct
intravitr
inject
mice
littl
ng
sirna
show
robust
uptak
retina
histolog
section
fluoresc
microscopi
hour
follow
inject
enthusiasm
direct
ocular
administr
sirna
treat
diseas
like
amd
grew
number
favor
earli
report
mani
group
led
initi
sever
clinic
trial
see
rnai
therapi
target
gene
involv
choroid
neovascular
eye
vascular
endotheli
growth
factor
vegf
receptor
ocular
sirna
drug
still
promis
enthusiasm
approach
wane
follow
report
cellsurfac
receptor
recogn
sirna
downstream
effect
innat
immun
respons
respons
earli
success
report
prevent
neovascular
recent
report
show
subretin
inject
sirna
trigger
induc
retin
degener
complic
optic
deliveri
sirna
clinic
trial
clinic
trialsopt
deliveri
bevasiranib
first
introduc
clinic
trial
opko
health
inc
sinc
phase
ii
trial
complet
sirna
vegf
becam
first
phase
iii
drug
class
therapeut
howev
studi
termin
base
recommend
independ
data
monitor
committe
http
studi
aim
treatment
wet
amd
addit
phase
ii
studi
bevasiranib
complet
treatment
diabet
macular
edema
dme
phase
iii
trial
announc
http
wet
amd
studi
diseas
sirna
drug
clinic
trial
phase
ii
studi
sponsor
allergan
chemicallymodifi
sirna
target
vegf
test
doseescal
studi
intravitr
inject
patient
choroid
neovascular
wet
amd
singl
dose
rang
welltoler
mean
foveal
thick
reduc
two
week
follow
dose
decreas
pronounc
dose
like
bevasiranib
shown
welltoler
safeti
standpoint
trial
termin
result
lack
improv
visual
acuiti
pfizer
quark
pharmaceut
studi
phase
two
phase
ii
clinic
trial
treatment
amd
sirna
sequenc
target
differ
proangiogen
factor
intravitrealdeliv
sirna
phase
trial
http
indic
welltoler
howev
object
studi
deem
achiev
trial
termin
http
drug
term
evalu
phase
ii
trial
treat
wet
amd
combin
lucenti
antivegf
antibodi
http
us
food
drug
administrationapprov
therapi
wet
amd
includ
macugen
pegaptanib
lucenti
ranibizumab
treatment
drug
extrem
effect
challeng
new
sirnabas
therapi
show
better
perform
quark
pharmaceut
initi
phase
doseescal
studi
studi
sirna
intravitr
administr
therapi
nonarterit
anterior
ischem
optic
neuropathi
naion
http
chemicallymodifi
sirna
sequenc
target
sylenti
develop
therapi
ocular
hypertens
use
sirna
target
adrenerg
receptor
http
phase
trial
test
safeti
effect
intraocular
pressur
use
topic
administr
eye
drop
show
advers
effect
phase
ii
trial
open
evalu
toler
therapeut
effect
sirna
patient
elev
intraocular
pressur
http
im
administr
protein
atelocollagen
see
use
im
deliveri
unmodifi
sirna
target
myostatin
treatment
muscular
dystrophi
sirna
atelocollagen
inject
bicep
femori
muscl
mice
inject
scrambl
sirnaatelocollagen
formul
contralater
muscl
serv
neg
control
sirnatr
muscl
show
signific
increas
muscl
mass
two
week
follow
singl
im
inject
morgan
colleagu
report
direct
inject
sirna
cardiac
muscl
singl
dose
nake
unmodifi
sirna
target
sodiumhydrogen
exchang
inject
left
ventricl
protein
mrna
reduc
hour
respect
addit
rtqpcr
result
cardiac
tissu
hour
follow
sirna
deliveri
suggest
presenc
bystand
effect
examin
tissu
locat
site
inject
left
ventricl
heart
also
show
knockdown
suggest
sirna
may
spread
neighbor
cellstissu
via
gap
junction
oral
administr
compound
suitabl
oral
administr
small
molecul
drug
formul
releas
activ
agent
stomach
small
intestin
absorpt
gut
mucosa
eventu
releas
circulatori
system
environ
quit
harsh
drug
deliv
way
experi
wide
swing
ph
prolong
exposur
varieti
nucleas
well
proteas
lipas
oral
administr
sirna
remain
lofti
goal
seem
unlik
true
system
deliveri
easili
achiev
although
tillman
colleagu
report
success
oral
deliveri
singlestrand
aso
doublestrand
sirna
high
molecular
weight
even
compound
surviv
harsh
gastrointestin
environ
would
larg
exclud
uptak
gut
epithelia
subsequ
escap
circulatori
system
therefor
discuss
common
rout
system
deliveri
small
molecul
appropri
highlight
head
local
deliveri
sinc
oral
administr
sirna
may
easili
find
applic
treat
local
diseas
within
gastrointestin
system
wilson
colleagu
design
thioket
deliveri
system
select
degrad
presenc
reactiv
oxygen
speci
produc
intestin
epithelium
case
orallydeliv
sirna
target
tnf
proinflammatori
cytokin
induc
intestin
inflamm
requir
releas
sirna
thioket
deliveri
system
colitisinduc
mice
dose
oral
gavag
mgkg
sirna
daili
day
sacrif
day
determin
sirna
uptak
function
target
tissu
induc
colon
inflamm
coupl
thioketalformul
particl
led
increas
releas
sirna
select
region
inflamm
also
colon
tnf
level
significantli
reduc
base
rtqpcr
analysi
mrna
harvest
tissu
addit
thioket
work
group
also
develop
peicondens
sirna
plga
nanoparticl
deliveri
system
reduc
tnf
inflam
colon
tissu
antitnfsirna
nanoparticl
show
tenfold
decreas
colon
tnf
express
dose
oral
cours
day
compar
control
sirna
exploit
mobil
immun
cell
aouadi
colleagu
demonstr
system
effect
oral
deliveri
sirna
encapsul
shell
gerp
essenti
porou
shell
extract
yeast
oral
gavag
gerp
contain
sirna
mice
result
suppress
mrna
macrophag
isol
varieti
tissu
includ
lung
liver
spleen
well
decreas
tnf
periton
caviti
follow
lipopolysaccharid
stimul
thought
gerp
taken
resid
macrophag
gutassoci
lymphoid
tissu
normal
immun
cell
traffick
result
system
spread
macrophag
bear
oral
dose
sirna
group
later
report
improv
technolog
sirna
cargo
complex
peptid
deliveri
tool
endoport
new
formul
show
improv
deliveri
particularli
effect
macrophagespecif
target
ip
administr
current
clinic
trial
ongo
use
chemic
synthes
sirna
oral
deliveri
human
howev
oral
transkingdom
express
shrna
tkrnai
drug
target
call
current
recruit
patient
phase
trial
marina
biotech
treatment
famili
adenomat
polyposi
deliveri
rout
sellick
colleagu
employ
direct
cochlear
administr
nake
sirna
elucid
function
inner
ear
protein
proofofprincipl
studi
group
demonstr
direct
cochlear
deliveri
possibl
still
preserv
auditori
function
fluoresceintag
sirna
administ
use
micropipett
directli
endolymphat
compart
cochlear
duct
dyelabel
sirna
enter
stria
vasculari
sever
ion
transport
channel
involv
hear
local
nakamura
colleagu
develop
octaargininemodifi
multifunct
envelopetyp
nanoparticl
devic
sirna
deliveri
complex
sirna
form
particl
nm
diamet
effici
deliv
sirna
vitro
minimum
toxic
akita
colleagu
coupl
fusogen
peptid
gala
particl
employ
ex
vivo
deliveri
sirna
target
bone
marrowderiv
dc
bmdc
ex
vivo
silenc
led
increas
product
bmdc
confirm
western
blot
likewis
cytokin
tnf
increas
bmdc
compar
use
control
sirna
ex
vivo
treat
bmdc
inject
footpad
mice
subsequ
sc
tumor
challeng
show
bmdc
lead
dramat
decreas
rate
tumor
growth
cours
day
play
key
role
immun
recognit
foreign
tissu
may
involv
kidney
allograft
reject
ripol
colleagu
deliv
unmodifi
sirna
rat
kidney
ex
vivo
via
intraarteri
infus
sirna
water
treat
kidney
subsequ
transplant
rat
monitor
day
posttranspl
histolog
analysi
show
transplant
kidney
treat
sirna
reduc
featur
characterist
humor
reject
suggest
success
intervent
graft
reject
process
method
select
suppress
express
target
gene
remark
use
tool
studi
role
gene
function
normal
patholog
state
past
five
year
seen
explos
use
sirna
research
tool
anim
model
experi
yet
routin
use
gene
knockdown
technolog
vivo
almost
becom
expect
journal
technolog
exist
suppress
level
gene
target
desir
deliveri
technolog
fulli
caught
safe
effici
deliveri
nucleic
acid
effector
molecul
desir
tissu
remain
greatest
limit
widespread
adopt
technolog
vitro
use
rnai
method
becom
widespread
varieti
potenti
problem
emerg
complic
interpret
experi
ote
immun
stimul
suppress
nontarget
gene
unintend
interact
sirna
mirnapathway
process
via
seedregion
homolog
time
underli
mechan
unwant
ote
elucid
method
prevent
circumv
wide
avail
particular
select
use
chemic
modif
una
residu
reduc
elimin
mani
mirnapathway
class
ote
help
evad
stimul
innat
immun
system
mani
cell
line
adapt
growth
vitro
longer
capac
respond
dsrna
foreign
molecul
stimul
innat
immun
system
signific
concern
vivo
prudent
modifi
sirna
use
anim
work
especi
use
polymerand
lipidbas
deliveri
tool
maxim
exposur
sirna
cargo
endosom
compart
tlr
resid
vivo
studi
includ
monitor
immun
stimul
sirna
andor
deliveri
tool
even
appropri
chemic
modif
strategi
employ
crucial
use
deliveri
system
success
vivo
sirna
experi
deliveri
vehicl
sourc
toxic
andor
ote
new
deliveri
tool
constantli
develop
hope
address
concern
breakthrough
deliveri
technolog
pave
way
final
make
anim
experiment
commonplac
final
frontier
sirna
technolog
use
drug
human
number
clinic
trial
alreadi
progress
addit
new
trial
plan
begin
next
year
local
administr
avoid
mani
complic
seen
system
deliveri
therefor
ocular
topic
therapi
greatest
potenti
move
forward
quickli
recent
advanc
lipid
nanoparticl
chemistri
look
particularli
favor
liver
deliveri
seem
like
hepat
diseas
may
first
area
wide
approach
use
systemiciv
rout
administr
final
note
branch
scienc
novel
method
rnai
field
quickli
publish
rapidli
gener
widespread
enthusiasm
prudent
recal
mani
excit
report
discuss
herein
yet
reproduc
outsid
group
independ
valid
necessari
step
supplementari
materi
tabl
import
featur
report
employ
synthet
sirna
vivo
